

1 **Peer Review Information:**

2 Nature Cell Biology thanks Laurent David and the other, anonymous, reviewer(s) for their contribution
 3 to the peer review of this work.

4

5 **Editor summary:**

6 Carbognin, Carlini, Panariello et al. report that ESRRB drives activation of the transcriptional program
 7 regulating the formative transition of naïve embryonic stem cells.

8

9

10 **1. Extended Data**

Figure or Table # Please group Extended Data items by type, in sequential order. Total number of items (Figs. + Tables) must not exceed 10.	Figure/Table title One sentence only	Filename Whole original file name including extension. i.e.: Smith_ED_Fig1.jpg	Figure/Table Legend If you are citing a reference for the first time in these legends, please include all new references in the main text Methods References section, and carry on the numbering from the main References section of the paper. If your paper does not have a Methods section, include all new references at the end of the main Reference list.
Extended Data Fig. 1	Gene signatures of different pluripotent states	Carbognin_ED_Fig1.jpg	a: Line chart showing dynamics of mRNA expression based on qPCR of four pluripotency markers (<i>Tfcp2l1</i> , <i>Esrrb</i> , <i>Sall4</i> , <i>Oct4</i>) in E14 cells during monolayer differentiation (withdrawal of either 2iL or 2i for 96h) both in 2iL (purple) and 2i (green). White circles indicate the mean of n=4 independent experiments, shown as dots. P-values indicate two-sided unpaired t-test between the indicated time points. b: Heatmaps showing Z-score normalised expression of all genes of each group (defined in Fig. 1d) in E14 cells differentiating from 2iL (purple box) and 2i (green box). Integration of n=2 independent biological replicates for each time point. See also Supplementary Table 2 for the biological processes enriched in the 6 signatures.
Extended Data Fig. 2	Transcriptional response	Carbognin_ED_Fig2.jpg	a: Bar plot showing the number of AP positive colonies in the clonal assay of

	<p>changes during commitment</p>	<p>cells cultured in 2iL and during differentiation (purple bars) and of cells in which 2iL was re-applied for 24h at the indicated time point (yellow bars, re-induction). Bars indicate mean +/-SD of n=8 independent experiments, shown as dots. Only the sample '24' was measured in n=4 independent experiments. Two-sided unpaired Student t-test.</p> <p>b: Heatmaps showing Z-score normalised expression of selected genes for each group (naive, formative, committed) during differentiation and re-induction. Integration of n=4 independent experiments for each time point.</p> <p>c: Barplots showing expression by RNAseq of Jak/Stat direct targets (Socs3 and Stat3, orange), WNT targets (Cdx2 and Axin2, green) and FGF targets (Dusp6 and Spry4, purple) in differentiating cells and after re-induction with 24h of LIF. Mean +/-SD of n=4 independent experiments.</p> <p>d: UCSC genome browser visualisation of normalised ATAC-seq profiles at the indicated loci. Rectangles indicate peaks found only in 2iL (green) or only at 48h (red). Integration of n=2 biological replicates.</p> <p>e: Volcano plot summarising published RNA-seq data⁹⁸ of ESCs cultured in Serum+LIF (S+L) or 2iL. Data were interpolated with the six groups of genes identified in Fig. 1 (naive early and late, formative early and late, committed early and late).</p> <p>f: Schematic representation of experimental strategy. Cells overexpressing pluripotency genes were mixed and differentiated for 96h. The clonal assay was then performed and cells were collected after 4 days. PCR on</p>
--	----------------------------------	--

			<p>genomic DNA was used to identify factors enriched in pluripotent colonies.</p> <p>g: Bar plot showing quantification of AP positive colonies of cells overexpressing an empty vector or pluripotency factors, either maintained in 2iL or differentiated for 96h. Bars indicate mean n=2 independent experiments, shown as dots.</p>
<p>Extended Data Fig. 3</p>	<p>Characterisation of ESC differentiation and regulation of Esrrb expression</p>	<p>Carbognin_ED_Fig3.jpg</p>	<p>a: Representative images of immunostaining for EpiSCs markers (Oct4 and T) in WT cells maintained in 2iL or differentiated for 96h in N2B27 or in presence of CHIR and Activin A to induce T expression. Scale bar=25µm. Similar results were obtained in n=2 independent experiments.</p> <p>b: Barplots showing expression by RNA-seq of key EpiSCs markers in WT cells maintained in 2iL or differentiated for 96h upon 2iL withdrawal. Mean of n=2 independent biological replicates is shown. n.d. indicates samples in which expression was undetectable or below 5 CPM.</p> <p>c: Violin plot showing quantification of mean intensity (arbitrary units) for ESRRB in E14 cells cultured in 2iL or differentiated for 48h, 96h or 120h (48, 96 120) or after reinduction with 2iL for 24h (48+24 and 96+24). At least 3 randomly selected fields for each sample have been measured. N=3 independent experiments were analysed. Each violin indicates an independent experiment.</p> <p>d: Left: Representative images of clonal assay followed by Alkaline Phosphatase staining of cells either maintained in 2iL or differentiated for 96h with or without the Gsk3 inhibitor CHIR (96+CHIR). Centre: Bar plot showing quantification of AP positive colonies. Bars indicate mean of 2 biological replicates, shown as dots. Right: Bar plot showing relative</p>

			<p>mRNA expression, measured by qPCR, for <i>Esrrb</i>. Bars indicate mean of 2 biological replicates, shown as dots.</p> <p>e: Barplot showing expression by qPCR of <i>Esrrb</i> in E14 cells cultured in 2iL, N2B27, ActivinA (20ng/ml), FGF2 (12.5 ng/ml) and inhibitors of TGF-beta (A83-01, 1 μM) and FGF signalling pathways (PD173074, 0.5 μm) for 48h. Mean +/- SD of 3 independent biological replicates are shown as dots.</p> <p>f: ChIP-PCR analysis of E14 cells cultured in 2iL and differentiated for 24h, 48h, 72h and 96h in N2B27. Immunoprecipitation was performed using anti-ESRRB and anti-H3K27ac antibody followed by PCR with primers located on <i>Esrrb</i> intron or <i>Tfcp2l1</i>, <i>Utf1</i> and <i>Tcf15</i> promoter regions. Fold-enrichment over a negative region is plotted. Mean +/-SD of n=4 independent experiments, shown as dots.</p>
<p>Extended Data Fig. 4</p>	<p>Regulation of <i>Esrrb</i> expression</p>	<p>Carbognin_E D_Fig4.jpg</p>	<p>a: Genome browser snapshot of histone modifications on regulatory regions on <i>Esrrb</i> gene in naive (2iL, blue) and formative (48h, red) states. Integration of n=2 biological replicates.</p> <p>b: Top: Representative images of immunostaining for H3K27ac (green) and ESRRB (red) in E14 cells cultured in 2iL, differentiated for 84h (84) or after a pulse with 2iLIF for 24h at 84h (2iL pulse), with or without Sodium Butyrate (NaButy or H2O) treatment. Nuclei were identified by DAPI staining (blue). Scale bar: 25μm. Bottom: Barplot showing quantification of mean intensity for H3K27ac (blue) and ESRRB (red) immunostaining normalised to the 2iL H2O samples. Mean +/-SD of n=3 independent experiments, shown as dots.</p>

			<p>c: Plots showing abundance of the indicated histone modifications detected by CUT&RUN and DNA methylation in naive (2iL, left) and formative cells (48, right), on regions bound by ESRRB only in 2iL ('2iL'), only at 48h ('48'), or in 2iL and after 48h ('2iL - 48'), identified in Fig. 4a-b. Integration of n=2 biological replicates. For '2iL' and '2iL - 48' regions we observed enrichment for H3K4me3, H3K27ac, H3K27me3 and H3K9me3 in naive cells. In formative cells, H3K4me3 and H3K9me3 decreased by ~50% while H3K27me3 was lost, while DNA methylation substantially increased. Those regions, where Esrrb binding increases at 48h ('48'), are heavily DNA methylated and pre-decorated by H3K4me3 and H3K27ac in naive cells, while the repressive marks H3K9me3 and H3K27me3 are absent.</p>
<p>Extended Data Fig. 5</p>	<p><i>Esrrb</i> KO clones characterization</p>	<p>Carbognin_ED_Fig5.jpg</p>	<p>a: Left: Bar plot showing the number of AP positive colonies after clonal assay of cells with loxP sites flanking the second exon of both alleles of <i>Esrrb</i> (<i>Esrrb</i> fl/fl, dark blue) and <i>Esrrb</i> KO cells generated by Cre-mediated recombination (light blue), cultured in 2iL and differentiated for 24h, 48h and 72h in N2B27. Mean +/- SD of n=3 independent experiments, shown as dots. Right: Barplots showing expression measured by qPCR of <i>Esrrb</i> in <i>Esrrb</i> fl/fl (dark blue) and <i>Esrrb</i> KO (light blue) cells cultured in 2iL and differentiated for 24h, 48h and 72h. Mean of n=2 independent experiments.</p> <p>b: Schematic representation of edited alleles of 3 CRISPR-generated <i>Esrrb</i> KO clones. The edited genome is indicated in red. The blue sequence is an insertion. Black bars indicate deletions.</p> <p>c: Bright field images of 3 CRISPR-generated <i>Esrrb</i> KO clones, cultured in 2iL and after 48h of 2iL withdrawal. Scale</p>

			<p>bar: 300µm.</p> <p>d: Barplot showing expression by RNAseq of naive markers in WT E14 cells and in 3 CRISPR-generated <i>Esrrb</i> KO clones. WT values were set as 1. Mean of n=2 biological replicates.</p>
Extended Data Fig. 6	Proliferation and viability analysis of <i>Esrrb</i> KO clones and FS differentiation	Carbognin_ED_Fig6.jpg	<p>a: Left: Proliferation assay over 4 days of WT cells and <i>Esrrb</i> KO clones, cultured in 2iL. Mean +/-SD of n=3 independent experiments is shown. Right: Barplot showing percentage of dead cells measured by Propidium iodide staining in two WT cell lines and 2 <i>Esrrb</i> KO clones. Boiled cells (95 degrees Celsius for 5 min) were used as positive control. Mean +/-SD of n=3 independent experiments is shown. P-value calculated with One-way ANOVA followed by Tukey multiple pairwise-comparisons.</p> <p>b: Gene Set Enrichment Analysis (GSEA) of key markers of Apoptosis and cell stress in WT and <i>Esrrb</i> KO cells cultured in 2iL (naive) and 48h (formative), which failed to detect any significant differences between WT and KO cells. P-values calculated by the GSEA software.</p> <p>c: Expression measured by qPCR of selected naive and formative genes in WT E14 cells (grey) and three <i>Esrrb</i> KO clones (blue) cultured in 2iL and after 24h, 48h and 72h of differentiation in N2B27. Mean of n=2 biological replicates is shown.</p> <p>d: Expression measured by qPCR of naive and lineage markers in Conditional <i>Esrrb</i> cells kept in 2iL+DOX. WT cells and <i>Esrrb</i> KO expressing a DOX-inducible empty vector (iEmpty) kept in 2iL+DOX are used as controls. Mean +/- SD n=3 independent experiments (dots) is shown.</p> <p>e: Gene expression of formative genes</p>

			<p>measured by qPCR in Conditional <i>Esrrb</i> cells cultured in 2iL+DOX (3rd bar) and withdrawn of 2iL and DOX for 48h (4th bar). <i>Esrrb</i> KO and WT cells expressing an inducible Empty vector (iEmpty) differentiated for 48h were used as controls (2nd and 6th bars). Bars indicate mean +/-SD of n=5 independent experiments, shown as dots. One-way ANOVA followed by Tukey multiple pairwise-comparisons.</p> <p>f: Left: Experimental strategy used for FS cells generation from ESCs. Right: Representative images of WT cells cultures in AloXR medium for 3 passages (P1, P2 and P3). Scale bar: 25µm. Similar results were obtained in n=3 independent experiments.</p> <p>g: Relative mRNA expression measured by qPCR of naive and formative genes in E14 cells cultured in 2iL or AloXR medium for up to 3 passages. Mean of n=3 technical replicates.</p>
<p>Extended Data Fig. 7</p>	<p>FS cell differentiation of <i>Esrrb</i> KO clones</p>	<p>Carbognin_E D_Fig7.jpg</p>	<p>a: Gene Set Enrichment Analysis (GSEA) of key markers of Apoptosis and cell stress in WT and <i>Esrrb</i> KO cells cultured in 2iL (naive) and P1/48h (formative) failed to detect any significant differences between WT and KO cells. P-values calculated by the GSEA software.</p> <p>b: PCA of RNA sequencing data of WT and <i>Esrrb</i> KO cells during FS differentiation. Genes contributing to Principal Components PC1 and PC3 are indicated. N=3 independent biological replicates, shown as dots, for 2iL samples. N=4 for P1-P3 samples. N=2 for KO3 at P2 and P3.</p> <p>c: Heatmaps showing mean normalised relative mRNA expression measured by qPCR of naive and formative genes in WT and <i>Esrrb</i> KO cells cultured in 2iL or AloXR medium for up to 3 passages (P1,</p>

			<p>P2, P3). Mean of n=3 technical replicates.</p> <p>d: Representative images of immunostaining for TFCP2L1 and OTX2 in WT cells (left panels) and for OTX2 in <i>Esrrb</i> KO cells (right panels) cultured in 2iL or AloXR medium for up to 3 passages. Nuclei were identified by DAPI staining (blue). Scale bar: 25µm. Similar results were obtained in n=2 independent experiments.</p> <p>e: Left: Representative images of WT and <i>Esrrb</i> KO cells cultured in FGF2+ActivinA+XAV for at least 6 passages, to induce EpiSCs differentiation. Scale bar: 25µm. Right: Barplots showing gene expression measured by qPCR of naive (<i>Esrrb</i> and <i>Klf4</i>), general pluripotency (<i>Oct4</i>) and EpiSCs (<i>Fgf5</i>, <i>T</i>) markers in WT and <i>Esrrb</i> KO cells cultured in FGF2+ActivinA+XAV for at least 6 passages, to induce EpiSCs differentiation. Embryo-derived EpiSCs (OEC2 and GOF18) and WT E14 ESCs cultured in 2iL are used as controls. Mean +/-SD of N=4 biological replicates, shown as dots.</p>
<p>Extended Data Fig. 8</p>	<p>PGCLC differentiation of <i>Esrrb</i> KO clones</p>	<p>Carbognin_E D_Fig8.jpg</p>	<p>a: Normalised frequency of individual gRNAs (indicative of KO) targeting <i>Esrrb</i> during induction of PGCLC (CRISPR screening results from⁵⁷). Dots indicate the mean of n=2 independent CRISPR screens.</p> <p>b: Left: Frequency of individual gRNA targeting <i>Esrrb</i> in EpiLC that have acquired correct formative status (<i>Stella</i>-) and EpiLC blocked from formative transition (<i>Stella</i>+). Note <i>Esrrb</i> gRNA (KO) are enriched in EpiLC that fail to acquire formative status, indicating a functional role for <i>Esrrb</i> in promoting the formative program. Right:</p>

		<p>Normalised frequency of individual gRNAs targeting Olfr568 as a representative negative control gene that should not influence the induction of PGCLC upon KO. Dots indicate the mean of n=2 independent CRISPR screens.</p> <p>c: Immunoblot of clonal lines derived from SGET ESC transiently transfected with Cas9 and gRNAs binding <i>Esrrb</i> coding sequence. Out of 5 independent <i>Esrrb</i> KO clones, 3 (A1.2, B2.1, A2.5) were randomly chosen for further validations. Beta-TUBULIN was used as loading control. The experiment was repeated 3 times with similar results. <i>Esrrb</i> KO clones do not display <i>Esrrb</i> protein expression, but a shorter mRNA can still be detected (Fig. 7d).</p> <p>d: Schematic representation of SGET activation during in vitro cell fate transitions of ESC (Stella+/Esg1+) into EpiLC (Esg1+) and early and late PGCLCs (Stella+) (adapted from Hackett et al., 2018).</p> <p>e: Total number of cells in SGET WT and <i>Esrrb</i> KO clones obtained after 3 days of PGCLC induction from EpiLC differentiation. Mean +/-SD of n=3 independent experiments (dots) is shown.</p> <p>f: Gene expression of selected genes in WT (grey) and n=3 independent <i>Esrrb</i> KO SGET lines (blue) at EpiLC, d3 and d5 PGCLC stages.</p> <p>g: Expression of the PGC-early (left) and PGC-late (right) geneset in EpiLC, d3 and d5 PGCLC from WT and <i>Esrrb</i> KO lines. Bars indicate the median, box indicates the 25th and 75th percentiles, whiskers represent median plus/minus the interquartile (25-75%) range multiplied by 2. Two-sided paired Student t-test, n.s. not significant.</p>
--	--	---

			<p>Integration of n=3 biological replicates for each sample.</p> <p>h: Gene expression of BMP direct targets in WT (grey) and n=3 independent <i>Esrrb</i> KO SGET lines (blue) at EpiLC, d3 and d5 PGCLC stages.</p>
<p>Extended Data Fig. 9</p>	<p>Differentiation of <i>Esrrb</i> KO clones in 2D and 3D</p>	<p>Carbognin_E D_Fig9.jpg</p>	<p>a: Heatmap showing Z-scored, mean-scaled, normalised gene expression, measured by RNA-seq, of master regulator genes for each of the three primary germ layers and trophoblast in WT cells and three <i>Esrrb</i> KO clones cultured in 2iL and after 24h, 48h and 72h of differentiation in N2B27. Integration of n=2 biological replicates for each sample.</p> <p>b: Representative images of WT cells cultured in N2B27 medium in matrigel for 48h, 72h or 96h, to allow 3D organisation and lumenogenesis. F-actin was labelled by Phalloidin staining (green) and immunostaining for the apical protein PODXL was performed (red). Scale bar: 30 μm. Similar results were obtained in n=5 independent experiments.</p> <p>c: Top: Barplot showing quantification of number of structured/field in WT and <i>Esrrb</i> KO cells cultured in N2B27 medium in matrigel for 48h, 72h or 96h. Bars indicate mean of 2 independent experiments, shown as dots. Centre: Violin plot showing quantification of Area (expressed in pixels) of >14 structures in WT and <i>Esrrb</i> KO cells. P-values calculated by two-way repeated measures ANOVA. Similar results were obtained in 3 independent experiments. Bottom: Violin plot showing quantification of the ratio of the 2 main diameters (roundness) of >17 structures in WT and <i>Esrrb</i> KO cells, as shown in the WT panel. P-values indicate two-sided unpaired t-test. Similar results</p>

			<p>were obtained in 3 independent experiments. Box plots show 1st, 2nd and 3rd quartile, whiskers represent median plus/minus the interquartile (25-75%) range multiplied by 1.5.</p> <p>d: Line plots showing quantification of F-ACTIN intensity along the diameter of 3D structures obtained by culturing WT and <i>Esrrb</i> KO cells in N2B27 in matrigel for 48h, 72h or 96h. At least 8 structures were quantified from n=2 independent experiments. The shades indicate the SD.</p> <p>e: Violin plots showing quantification of OTX2 intensity in 3D structures obtained from WT and <i>Esrrb</i> KO cells cultured in N2B27 in matrigel for 48h. N>380 nuclei for each sample. Two independent experiments are shown (left and right). Box plots show 1st, 2nd and 3rd quartile, whiskers represent median plus/minus the interquartile (25-75%) range multiplied by 1.5.</p>
<p>Extended Data Fig. 10</p>	<p>Network analysis of formative gene regulation by <i>Esrrb</i></p>	<p>Carbognin_E D_Fig10.jpg</p>	<p>a: Barplot showing expression of Otx2 measured by qPCR in ES cells treated for 48h with ActivinA (20ng/ml), FGF2 (12.5 ng/ml) and inhibitors of TGF-beta (A83-01, 1 μM) and FGF signalling pathways (PD173074, 0.5 μM). Cells cultured in 2iL or N2B27 for 48h were used as controls. Mean +/-SD of n=3 independent biological replicates (dots) are shown.</p> <p>b: Genome browser snapshot of histone modifications at Otx2 enhancer (E) bound by <i>Esrrb</i> and promoter (P), in naive and formative cells. Profiles are the integration of n=2 biological replicates.</p> <p>c: ABN derived from a Pearson correlation threshold of 0.56 (see Methods). Solid black lines indicate required and definite interaction, dashed</p>

			lines indicate optional interactions, red lines indicate disallowed interactions. Positive regulations are indicated by a black arrow, negative regulations are indicated by a black circle-headed line. d: Summary of 4 experimental constraints, each with initial (left column) and final (right column) conditions. Gene expression is discretized as high (blue) or low (white).
--	--	--	--

11

12 2. Supplementary Information:

13 A. PDF Files

Item	Present?	Filename	A brief, numerical description of file contents.
		Whole original file name including extension. i.e.: Smith_SI.pdf. The extension must be .pdf	i.e.: <i>Supplementary Figures 1-4, Supplementary Discussion, and Supplementary Tables 1-4.</i>
Supplementary Information	Yes	Carbognin_SI.pdf	Supplementary Figures 1-3
Reporting Summary	Yes	RS-Martello.pdf	
Peer Review Information	Yes	<i>TPRFile_Martello.pdf</i>	

14

15 B. Additional Supplementary Files

Type	Number	Filename	Legend or Descriptive Caption
	Each type of file (Table, Video, etc.) should be numbered from 1 onwards. Multiple files of the same type should be listed in sequence, i.e.: Supplementary Video 1, Supplementary Video 2, etc.	Whole original file name including extension. i.e.: <i>Smith_Supplementary_Video_1.mov</i>	Describe the contents of the file
Supplementary Table	1	Carbognin_Supplementary_Tables_1_2_3_4_5_6.xlsx	Supplementary Table 1: 6 genes signatures identified in this study.

			<p>Supplementary Table 2: Biological processes enriched in the 6 signatures identified.</p> <p>Supplementary Table 3: Biological processes enriched in genes bound by Esrrb.</p> <p>Supplementary Table 4: Primer List.</p> <p>Supplementary Table 5: gRNAs sequences.</p> <p>Supplementary Table 6: Antibody List.</p>
--	--	--	---

16

17 3. Source Data

Parent Figure or Table	Filename Whole original file name including extension. i.e.: <i>Smith_SourceData_Fig1.xls</i> , or <i>Smith_Unmodified_Gels_Fig1.pdf</i>	Data description i.e.: Unprocessed western Blots and/or gels, Statistical Source Data, etc.
Fig. 1	Carbognin_SourceData_Fig1.xlsx	Statistical Source Data
Fig. 2	Carbognin_SourceData_Fig2.xlsx	Statistical Source Data
Fig. 3	Carbognin_SourceData_Fig3.xlsx	Statistical Source Data
Fig. 5	Carbognin_SourceData_Fig5.xlsx	Statistical Source Data
Fig. 5	Carbognin_SourceData_Fig5.pdf	Unprocessed western Blots
Fig. 6	Carbognin_SourceData_Fig6.xlsx	Statistical Source Data
Fig. 7	Carbognin_SourceData_Fig7.xlsx	Statistical Source Data
Fig. 8	Carbognin_SourceData_Fig8.xlsx	Statistical Source Data

Extended Data Fig. 1	Carbognin_SourceData_E D_Fig1.xlsx	Statistical Source Data
Extended Data Fig. 2	Carbognin_SourceData_E D_Fig2.xlsx	Statistical Source Data
Extended Data Fig. 3	Carbognin_SourceData_E D_Fig3.xlsx	Statistical Source Data
Extended Data Fig. 4	Carbognin_SourceData_E D_Fig4.xlsx	Statistical Source Data
Extended Data Fig. 5	Carbognin_SourceData_E D_Fig5.xlsx	Statistical Source Data
Extended Data Fig. 6	Carbognin_SourceData_E D_Fig6.xlsx	Statistical Source Data
Extended Data Fig. 7	Carbognin_SourceData_E D_Fig7.xlsx	Statistical Source Data
Extended Data Fig. 8	Carbognin_SourceData_E D_Fig8.xlsx	Statistical Source Data
Extended Data Fig. 8	Carbognin_SourceData_E D_Fig8.pdf	Unprocessed western Blots
Extended Data Fig. 9	Carbognin_SourceData_E D_Fig9.xlsx	Statistical Source Data
Extended Data Fig. 10	Carbognin_SourceData_E D_Fig10.xlsx	Statistical Source Data

18

19

20 **Esrrb guides naive pluripotent cells through the**
 21 **formative transcriptional program**

22

23

24 **Author list**

25 Elena Carbognin^{1,12}, Valentina Carlini^{2,3,12}, Francesco Panariello^{4,12}, Martina Chierogato⁵, Elena
26 Guerzoni⁵, Davide Benvegnù⁵, Valentina Perrera¹, Cristina Malucelli¹, Marcella Cesana^{4,6},
27 Antonio Grimaldi⁴, Margherita Mutarelli^{4,7}, Annamaria Carissimo^{4,8}, Eitan Tannenbaum⁹,
28 Hillel Kugler⁹, Jamie A. Hackett^{2,13}, Davide Cacchiarelli^{4,10,11,13} and Graziano Martello^{5,13}
29

30 **Affiliations**

31 1: Department of Molecular Medicine, Medical School, University of Padua, Padua, Italy.

32 2: Epigenetics & Neurobiology Unit, European Molecular Biology Laboratory (EMBL)-Rome,
33 Adriano Buzzati-Traverso Campus, Rome, Italy.

34 3: Collaboration for joint PhD degree between EMBL and Heidelberg University, Faculty of
35 Biosciences, Heidelberg, Germany

36 4: Telethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of
37 Integrative Genomics, Pozzuoli, Italy

38 5: Department of Biology, University of Padua, Padua, Italy.,

39 6: Department of Advanced Biomedical Sciences, University of Naples “Federico II”, Naples, Italy

40 7: Istituto di Scienze Applicate e Sistemi Intelligenti "Eduardo Caianiello", Consiglio Nazionale
41 delle Ricerche, Pozzuoli, Italy

42 8: Istituto per le Applicazioni del Calcolo "Mauro Picone," Consiglio Nazionale delle Ricerche,
43 Naples, Italy

44 9: The Faculty of Engineering, Bar-Ilan University, Ramat Gan, Israel

45 10: Department of Translational Medicine, University of Naples “Federico II”, Naples, Italy

46 11: School for Advanced Studies, Genomics and Experimental Medicine Program, University of Naples
47 “Federico II”, Naples, Italy

48 12: These authors contributed equally

49 13: These authors jointly supervised this work

50

51 Correspondence to: jamie.hackett@embl.it (J.A.H.), d.cacchiarelli@tigem.it (D.C.),

52 graziano.martello@unipd.it (G.M.)

53 **Abstract**

54 During embryonic development, naive pluripotent epiblast cells transit to a formative state. The
55 formative epiblast cells form a polarised epithelium, exhibit distinct transcriptional and epigenetic
56 profiles and acquire competence to differentiate into all somatic and germline lineages. However,
57 we have limited understanding of how the transition to a formative state is molecularly controlled.
58 Here we used murine ESC models to show that ESRRB is both required and sufficient to activate
59 formative genes. Genetic inactivation of *Esrrb* leads to illegitimate expression of mesendoderm
60 and extraembryonic markers, impaired formative expression and failure to self-organise in 3D.
61 Functionally, this results in impaired ability to generate Formative Stem cells and primordial germ
62 cells in the absence of *Esrrb*. Computational modelling and genomic analyses revealed that
63 ESRRB occupies key formative genes in naive cells and throughout the formative state. In so
64 doing, ESRRB kickstarts the formative transition, leading to timely and unbiased capacity for
65 multi-lineage differentiation.

66 **Main text**

67 In mouse embryos, naive pluripotent cells exist from embryonic day (E) 3.5 to E4.75¹⁻³. Upon
68 implantation (E5.0 – E6.5) epiblast cells undergo a maturation phase, named “formative”
69 pluripotency”, characterised by epithelial polarisation, lumenogenesis⁴ and transcriptional
70 changes in preparation for differentiation^{2,3,5-7}. Cells in the formative phase downregulate naive
71 pluripotency markers, upregulate epigenetic modifiers and become competent for both unbiased
72 germ layer formation and primordial germ cell (PGC) specification (E6.5 - E7.5)^{5,7-10}. What factors
73 guide pluripotent cells through such a series of molecular changes?

74
75 Embryonic development entails transitions through pluripotent states, which can be captured in
76 vitro. Mouse embryonic stem cell (ESCs) are obtained from naive cells of the preimplantation
77 embryo, with whom they share similar transcriptional and epigenetic profiles, and metabolic
78 activity^{1,11-13}. Naive ESCs were originally cultured in the presence of the cytokine LIF together
79 with Foetal Bovine Serum (Serum+LIF)^{14,15}. More recently, a chemically defined culture condition,
80 based on 2 inhibitors (2i, PD0325901 (PD)=Mek inhibitor and CHIR99021 (CHIR) =GSK3
81 inhibitor) allowed the expansion of a homogeneous population of naive ESCs¹⁶. Adding LIF to 2i
82 (2iL) makes the culture more robust and delays the process of differentiation^{17,18}.

83 Formative Stem (FS) cells have been obtained from embryos or from ESCs using ALoXR or other
84 media^{5,7,19}. They display inactivation of naive factors and induction of formative genes, including
85 Otx2 that is crucial for their self-renewal.

86
87 We analysed gene expression changes during the irreversible exit from the naive state. After
88 extinction of the naive pluripotency program a second program, compatible with a formative state,
89 is transiently activated and cells irreversibly commit to differentiate. We found that Esrrb is both
90 sufficient and required to induce formative genes. In the absence of Esrrb, differentiation is

91 skewed towards mesendoderm and trophectoderm, PGCs formation is severely impaired and FS
92 cells cannot be obtained, indicating a critical role of ESRRB in chaperoning pluripotent cells
93 through the initial phases of differentiation.

94 **Transcriptional changes during exit from naive** 95 **pluripotency**

96 Upon withdrawal of 2iL, ESCs enter a reversible phase in which they self-renew if 2iL is reapplied.
97 If 2iL withdrawal is further prolonged, all ESCs will commit to differentiation and lose self-renewal
98 capacity^{10,17,20} (Fig. 1a). We measured the kinetics of ESC commitment starting from 2i or 2iL.
99 After signals withdrawal, cells were left in N2B27 medium, which induces neural differentiation²¹.
100 Every 12 hours we quantified the percentage of self-renewing cells, forming undifferentiated
101 colonies in a clonal assay. Cells differentiating from 2iL maintain full self-renewal capacity for up
102 to 48 hours (h), despite the changes in morphology (Fig. 1b) and the strong reduction in the naive
103 pluripotency markers^{22–26} (Extended Data Fig. 1a). After 84h all cells committed and lost self-
104 renewal capacity.

105
106 We performed a transcriptome analysis followed by Principal Component Analysis (PCA).
107 Progression along Principal Component (PC) 1 indicated a reduction of naive genes *Tfcp2l1* and
108 *Nanog* and induction of neuroectoderm genes *Sox1* and *Sox11*. Along PC 2 we detected transient
109 activation of the formative markers *Otx2*, *Pou3f1*, *Sox3*, *Fgf5*, *Lef1*, *Hes6* and *Dnmt3a/b*^{5,6,27–29}
110 (Fig. 1c).

111
112 Unsupervised hierarchical clustering on samples differentiating from 2iL identified 6 groups of
113 genes ('gene signatures', Fig. 1d, Extended Data Fig. 1b). Two signatures were highly expressed
114 in 2iL and downregulated more or less rapidly ("naive early" and "naive late" gene signatures).
115 Several formative markers (*Etv4*, *Etv5*, *Dnmt3a*, *Dnmt3b*, *Lef1*, *Pou3f1*, *Otx2*, *Sox3*)^{6,27–30} were
116 transiently upregulated during the reversible phase. Thus, we defined 2 signatures as "formative
117 early" and "formative late", reaching maximal expression at 24-36h and 60h. Genes lowly

118 expressed in 2iL, reaching their maximum in committed cells at 84h or 96h, formed the “early
119 committed” and “late committed” signatures (Supplementary Table 1).

120 Full activation of the formative programs was associated with gradual loss of reversibility, as
121 reported^{10,31}. Cells differentiating from 2i show faster kinetics¹⁷. The 2iL and 2i time series
122 displayed striking similarities in gene expression changes, with 2i cells showing anticipation by
123 ~24h (Fig. 1b-c, Extended Data Fig. 1a-b and Supplementary Table 2).

124

125 Analysis of embryo data³² revealed that the two naive gene signatures were enriched in E4.5
126 genes, the formative signatures were enriched in E5.5 genes and the committed signatures in
127 E6.5 genes (Fig. 1d), indicating that our *in vitro* assay recapitulates transcriptional changes
128 observed in the embryo.

129

130 We then asked whether commitment affected the response to 2iL. After 48h of differentiation cells
131 responded to 2iL by upregulating naive markers, downregulating formative markers and were fully
132 clonogenic (Extended Data Fig. 2a-b). In contrast, after 96h cells failed to form colonies after
133 reinduction, failed to reactivate naive markers and further upregulated committed markers.
134 However, analysis of direct targets of JAK/STAT, WNT and FGF revealed that the responsiveness
135 of key signalling pathways was not significantly changed after commitment (Extended Data Fig.
136 2c). We conclude that commitment is associated with a change in the interpretation of external
137 signals.

138

139 **Reversibility is associated with *Esrrb* expression**

140 Different transcriptional responses to signals could be due to changes in chromatin accessibility,
141 thus we performed Assay for Transposase-Accessible Chromatin followed by sequencing (ATAC-
142 seq). We identified regions accessible only in 2iL (*Tfcp2l1* locus), only at 48h, maintained

143 throughout the reversible phase (*Lef1* locus) or accessible only after commitment (Fig. 2a and
144 Extended Data Fig. 2d). Transcription factors motif analysis (Fig. 2b) revealed an enrichment for
145 SOXs, TCF3, ESRRB and KLFs in 2iL; in the reversible phase (2iL - 48h) we found motifs of
146 ESRRB, KLFs and NFYA/B together with SMAD3 and ETS, downstream mediators of the TGF-
147 beta and FGF pathways, which promotes formative transition^{5,6,19,31}. Peaks found only at 48h were
148 enriched for the formative transcription factors ZIC3 and OTX2, for ASCL2 and for ESRRB and
149 MYB only on promoters. After commitment we observed enrichment for TEADs, SOXs, GLIS3,
150 JUN/FOS, ZIC3 and OTX2. Thus, chromatin accessibility is dynamically regulated during
151 commitment, with the persistence of accessible regions during the reversible phase, under the
152 control of SMAD3, ETSs, KLFs and ESRRB.

153

154 Culture of ESCs under Serum+LIF conditions, in the absence of feeders, generates a
155 heterogeneous population of pluripotent and partially differentiated cells^{3,10,18,33–36}. Consistently,
156 naive gene signatures were expressed at lower levels in Serum+LIF than in 2iL, while formative
157 and committed genes were more abundant in Serum+LIF (Extended Data Fig. 2e).

158 We took advantage of such heterogeneity and analysed the genome-wide binding profiles of
159 several pluripotency regulators and chromatin modifiers previously generated in Serum+LIF³⁷.

160 We calculated the relative enrichment of factors at the promoters of genes belonging to the 6
161 gene signatures, seeking potential regulatory mechanisms (Fig. 2c). The core pluripotency factors
162 POU5F1, known as OCT4, and SOX2 were found significantly enriched at all signatures.
163 Polycomb Repressive Complex 2 (PRC2) components were significantly bound to committed
164 genes. Interestingly, both naive and formative signatures were significantly bound by naive
165 pluripotency factors (KLF4, TFCP2L1, and ESRRB).

166

167 ESCs in the reversible phase express formative genes, which may be regulated by pluripotency
168 factors. We asked whether the forced expression of pluripotency factors enriched at naive and

169 formative signatures could extend the reversible phase during ESC differentiation. We generated
170 a pool of cells stably expressing individual factors, differentiated them for 96h and found that they
171 were still able to form naive colonies (Extended Data Fig. 2f and Fig. 2d). We extracted genomic
172 DNA from the pluripotent colonies, compared the frequency of genomic integration of each factor,
173 and observed a strong enrichment for *Esrrb* integration. We generated lines stably expressing
174 single factors, differentiated them individually and confirmed that *Esrrb* expression led to robust
175 colony formation (Fig. 2e and Extended Data Fig. 2g).

176 *Esrrb* has been shown to efficiently reset primed Epiblast Stem cells (EpiSCs) to naive
177 pluripotency^{38,39}. Committed cells at 96h might be EpiSCs and *Esrrb* could be in fact resetting
178 them. However, we failed to detect EpiSC-specific markers in committed cells (Extended Data
179 Fig. 3a-b). We conclude that *Esrrb* forced expression prolongs the reversible phase during ESC
180 differentiation.

181

182 We observed that *Esrrb* mRNA expression rapidly decreases upon 2iL withdrawal, with a ~90%
183 reduction after 48h. ESRRB protein is still present in most cells after 48h of differentiation from
184 2iL, becoming barely detectable at 96h (Fig. 2f and Extended Fig. 3c). Moreover, we observed
185 full reactivation after 2iL reinduction at 48h (48+24) and no response at 96h (96+24). These
186 results indicate that cells in the reversible phase express ESRRB protein and are capable to
187 reinduce *Esrrb* mRNA, while cells committed to differentiate have permanently lost *Esrrb*
188 expression, as also reported under Serum+LIF conditions⁴⁰.

189 To dissect the mechanism controlling *Esrrb* expression during differentiation we analysed the role
190 of both signalling pathways and epigenetics. *Esrrb* is a direct target of the repressor TCF7L1^{24,41}.
191 Treatment with CHIR, which causes derepression of TCF7L1 targets^{42,43}, elevated the expression
192 of *Esrrb* for 96h, accompanied by extended reversibility (Extended Data Fig. 3d-e). FGF had a
193 minor negative effect on *Esrrb* expression. We then analysed the epigenetic profile of the *Esrrb*

194 locus. In 2iL and at 48h ESRRB strongly binds to his intronic enhancer⁴⁴ (Extended Data Fig. 3f),
195 compatible with reactivation of *Esrrb* mRNA expression upon 2i treatment. In 2iL this enhancer is
196 enriched for H3K27ac and H3K4me3. Both activating marks are then lost and H3K27me3 is
197 gained, leading to a complete silencing (Extended data Fig. 4a-b). We treated fully committed
198 cells with Sodium Butyrate (NaButy), a histone deacetylase inhibitor, and with 2i. In committed
199 cells H3K27ac and ESRRB protein levels were undetectable (Extended Data Fig. 4b). NaButy
200 treatment maintained H3K27ac levels. Upon 2iL pulse, ESRRB protein was strongly detected.
201 We conclude that *Esrrb* expression is positively controlled by H3K27ac and 2i.

202

203 **Esrrb promotes the expression of formative genes**

204 Next, we generated cells expressing an *Esrrb*-IRES-Venus (EIV) transgene under a Doxycycline
205 (DOX)-inducible promoter, to induce *Esrrb* expression *specifically* during differentiation and to
206 isolate by FACS pure populations of *Esrrb*-IRES-Venus positive cells upon DOX induction or pure
207 *Esrrb*-IRES-Venus negative cells in the absence of DOX. Upon replating in 2iL, EIV⁺ cells robustly
208 formed naive colonies, confirming that *Esrrb* expression is sufficient to confer reversibility (Fig.
209 3a-b).

210 We performed transcriptional analysis and confirmed *Esrrb* induction in EIV⁺ cells, while a panel
211 of naive markers were only mildly expressed. Commitment genes were strongly repressed by
212 *Esrrb* expression. Surprisingly, several genes of the formative signatures (n=57) were highly
213 induced (Fig. 3c-e). We conclude that *Esrrb* expression during differentiation results in activation
214 of both naive and formative genes.

215

216 Our results suggest a role of ESRRB as a positive activator of the formative gene program, beside
217 its role as a naive factor^{22-24,45}. To further investigate this, we performed Chromatin
218 Immunoprecipitation (ChIP)-sequencing for ESRRB. The large majority of ESRRB binding occurs

219 in 2iL and at 48h (Fig. 4a-b). Several formative genes promoters are bound by ESRRB in 2iL and
220 at 48h (2iL – 48), in line with its capacity to induce their expression. ESRRB peaks on naive genes
221 (e.g. *Tfcp2l1*) decrease after 48h, supporting its role in sustaining the naive transcriptional network
222 (Fig. 4b-c and Extended Data Fig. 3f). On the contrary, peaks on formative genes are present in
223 2iL and the signal is maintained (or increased) at 48h. These observations endorse the concept
224 of *Esrrb* as a direct activator of the formative gene program during the reversible phase. A search
225 for biological processes enriched in genes bound by ESRRB identified Oxidative phosphorylation,
226 Krebs cycle and glycolysis (Supplementary Table 3), as reported⁴⁶.
227 How is ESRRB binding dynamically regulated between the naive and formative states? Previous
228 studies showed that ESRRB-bound regions are decorated by specific epigenetic marks^{38,47}.
229 Indeed, epigenetic profiling revealed differences in the levels of H3K27me3, H3K9me3 and DNA
230 methylation in ESRRB-bound regions in naive or formative states (Extended Data Fig. 4c).

231

232 **ESRRB activates both naive and formative programs**

233 Next, we asked whether *Esrrb* inactivation would shorten the reversible phase leading to more
234 rapid commitment. Transient knockdown of *Esrrb* (Fig. 5a) led to inability to form colonies after
235 48h and anticipated reduction of a naive marker. Similar results were obtained using *Esrrb* KO
236 ESCs previously generated by gene-targeting²⁴ (Extended Data Fig. 5a). We generated 3 *Esrrb*
237 KO clonal lines by CRISPR/Cas9 system in 2iL (Fig. 5b, Extended Data Fig. 5b), to exclude the
238 possibility that multiple rounds of gene-targeting and long-term culture in Serum+LIF could have
239 induced cell adaptation or selection. *Esrrb* KO clones showed no gRNAs off-target mutations
240 (Supplementary Fig. 1) and no morphological differences (Extended Data Fig. 5c), they displayed
241 long-term self-renewal in 2iL, although with a partial downregulation of some pluripotency markers
242 (Extended Data Fig. 5d), as reported^{24,48}. *Esrrb* KO lines showed reduced self-renewal capacity
243 relative to parental cells, consistently with the anticipated commitment of *Esrrb* KO cells (Fig. 5b,

244 bottom). The reduction in colony number could be due to viability impairment, as reported upon
245 acute *Esrrb* deletion^{38,41,47}. The proliferation rate and viability of *Esrrb* KO clones did not differ
246 from those of wild-type (WT) cells (Extended Data Fig. 6a). We obtained transcriptomes from
247 *Esrrb* WT and KO clones. Analysis of Apoptosis and Cell Stress signatures revealed no
248 differences (Extended Data Fig. 6b), further ruling out a viability impairment of *Esrrb* KO cells.
249 PCA indicated anticipated progression of *Esrrb* KO cells (Fig. 5c). Naive signatures were reduced
250 (84 genes) and committed genes were upregulated in *Esrrb* KOs (278 genes), in line with the
251 anticipated loss of self-renewal observed in clonal assays. Interestingly, formative genes were
252 globally downregulated (148 genes) in multiple *Esrrb* KO clones (Fig. 5d-e and Extended Data
253 Fig. 6c), confirming that *Esrrb* regulates both the naive and formative programs.

254

255 **ESRRB is required for generation of FS cells**

256 To uncouple the role of ESRRB in the maintenance of naive pluripotency from its role as activator
257 of the formative program we generated *Esrrb* KO cells expressing a DOX-inducible *Esrrb*
258 transgene ('Conditional *Esrrb* cells', Fig. 6a).

259 We gave a pulse of DOX between 24 and 48h, at the time of activation of the formative program
260 and observed induction of formative genes (*Tcf15*, *Dnmt3a*, *Dnmt3b* and *Utf1*, Fig. 6b).

261 In a complementary strategy, we expanded Conditional *Esrrb* cells in 2iL+DOX. Expression of
262 naive markers was comparable to the one observed in WT cells, with no spontaneous expression
263 of lineage markers (Extended Data Fig. 6d). We withdrew 2iL and DOX and ESRRB protein was
264 undetectable after 48h (Fig. 6c,d). We therefore asked whether acute loss of ESRRB would affect
265 formative gene expression. Global transcriptome profiling revealed impaired induction of 128
266 formative genes, including *Otx2*, *Utf1*, *Dnmt3a* and *Dnmt3b*, compared to WT cells (Fig. 6e-f and
267 Extended Data Fig. 6e). From these two experiments, whereby ESRRB is either specifically

268 added or acutely removed during formative gene activation, we conclude that ESRRB is an
269 inducer of formative genes, independently from its role as a naive factor.

270

271 FS cells have been obtained from embryos or from ESCs using A_{lo}XR medium¹⁹. If *Esrrb* is a
272 critical inducer of formative genes, it should not be possible to obtain *Esrrb* KO FS cells. After 3
273 passages in A_{lo}XR medium, WT cells rapidly downregulated naive genes and upregulated
274 formative markers (Extended Data Fig. 6f-g). WT cells could be easily stabilised in A_{lo}XR for >9
275 passages. In contrast, *Esrrb* KO clones displayed an aberrant morphology and repeatedly
276 collapsed soon after passage 3 (Fig. 6g).

277 We performed transcriptome analysis during FS conversion. Gene signatures of Apoptosis and
278 Cell Stress revealed no differences between *Esrrb* WT and KO (Extended Data Fig. 7a), thus
279 ruling out a general viability impairment of *Esrrb* KO cells. We looked for those early expression
280 alterations distinguishing WT from *Esrrb* KO cells. The formative genes *Otx2*, *Dnmt3a* and
281 *Dnmt3b* peaked after 48h (P1) and were then maintained at high levels in WT FS cells, but not in
282 *Esrrb* KO cells (Fig. 6h and Extended data Fig. 7b-c). Lineage markers *Nes*, *Hand1*, *Foxa2* and
283 *Cdkn1c* were significantly upregulated in *Esrrb* KO cells from P1. We conclude that *Esrrb* genetic
284 inactivation leads to inability to generate FS cells and impaired induction of formative genes.

285 *Esrrb* was detected only during the first 48h of FS cell generation (2iL and P1), and not in stably
286 expanding WT FS cells, indicating that *Esrrb* plays an early role during establishment of FS cells
287 and not for their maintenance. FS cells rely on the transcription factor *Otx2* for their self-renewal¹⁹.
288 In the absence of ESRBB most cells were devoid of OTX2 by passage 2 (Extended Data Fig. 7d),
289 in agreement with their collapse. We conclude that during FS cell establishment, ESRRB is
290 required for robust induction of formative genes.

291

292 Primed EpiSCs are an in vitro model of the peri-gastrulation epiblast⁴⁹⁻⁵¹ and are obtained from
293 either post-implantation embryos or ESCs^{39,52-54}. *Otx2* is required for FS cell identity, but

294 dispensable in EpiSCs^{19,30}. We asked whether EpiSCs could be obtained from *Esrrb* KO ESCs.
295 We applied AFX conditions⁵⁵ and both *Esrrb* WT and KO cells robustly expanded for >10
296 passages. *Esrrb* and *Klf4* were downregulated, *Oct4* was maintained and EpiSC-specific markers
297 *Fgf5* and *T* were partially induced (Extended Data Fig. 7e). We conclude that ESRRB is
298 dispensable for EpiSCs generation.

299

300 **PGCs specification is impaired by loss of ESRRB**

301 Competence for PGC specification is acquired in the formative state^{5-7,10}. To become responsive
302 to inductive signals for germ cell specification, ESCs must extinguish their naive identity and
303 transit to epiblast-like cells(EpiLCs). EpiLCs are molecularly similar to the formative epiblast^{6,56}.
304 ESRRB is crucial for the induction of the formative program, thus PGC specification should be
305 impaired in the absence of *Esrrb*. Indeed, a CRISPR-Cas9 genome-wide screen showed that
306 gRNAs targeting *Esrrb* were underrepresented both in formative EpiLCs and in PGCLCs⁵⁷
307 (Extended Data Fig. 8a-b).

308 Thus, we sought to confirm the role of ESRRB as a regulator of PGC specification by generating
309 novel clonal *Esrrb* KO lines in the *Stella*-GFP:*Esg1*-tdTomato (SGET)⁵⁷ reporter ESC line
310 (Extended Data Fig. 8c-d), which did not show any mutations in predicted off-targets
311 (Supplementary Fig. 2).

312 *Esrrb* KO lines exhibited reduced capacity to specify *Stella*+ PGCLC at both day 3 and day 5, as
313 compared to WT cells (Fig. 7a). This reduction was not due to impaired proliferation or survival of
314 *Esrrb* KO cells, given that in our experiments we replated equal numbers of *Esg1*+ EpiLCs and
315 observed no differences in the number of cells after PGCLC induction (Extended Data Fig. 8e).

316 We isolate those few *Stella*+ PGCLC that were derived from *Esrrb* KO lines by flow cytometry
317 and analysed them by RNAseq. WT and KO cells follow a different trajectory during PGCs
318 specification suggesting that the developmental programs are not appropriately activated in *Esrrb*

319 KO cells (Fig. 7b). Formative genes (*Fgf5*, *Dnmt3a*, *Etv5*, *Utf1*, *Otx2*) were significantly reduced
320 in *Esrrb* KO EpiLCs (Fig. 7c-d and Extended Data Fig. 8f). Moreover, we observed significant
321 downregulation of both early and late PGCs genesets in *Esrrb* KO PGCLC (Extended Data Fig.
322 8g), corroborating the idea that the full germline program was not appropriately activated. Several
323 PGC markers, such as *Dazl*, *Kit*, *Nanog* and *Tfcp2l1* failed to activate fully in *Esrrb* KO cells,
324 although we observed expected activation of the core PGC markers *Prdm14*, *Blimp1* and
325 *Tfap2c/Ap2y*. We conclude that the absence of *Esrrb* leads to a loss of robustness in PGCs
326 specification.

327 Previous studies have indicated that *Esrrb* promotes PGC specification via BMP4 production from
328 the extraembryonic ectoderm⁵⁸. In our system we provide excess of exogenous BMP4 and BMP8.
329 We measured the expression of 6 BMP direct transcriptional targets⁵⁹ during PGCLC induction
330 and found no differences upon *Esrrb* deletion (Extended Data Fig. 8h). We conclude that *Esrrb*
331 promotes PGC specification both via BMP-independent and BMP-dependent mechanisms.

332
333 Further transcriptional analyses revealed that *Esrrb* KO cells robustly expressed somatic-
334 mesodermal markers (*Pitx2*, *Pbx1*, *Lefty1*, *FoxP1*) at both EpiLC and PGCLC stages (Fig. 7d).
335 Similarly, during neural differentiation in N2B27 all *Esrrb* KO cells display a robust expression of
336 markers of mesoderm, endoderm and trophectoderm (Extended Data Fig. 9a).

337 Taken together these results endorse the role of *ESRRB* as a key coordinator of the formative
338 gene program that is preparatory for unbiased germ-layer and germ-cell differentiation. In the
339 absence of *ESRRB*, PGC specification is impaired and mesoderm, endoderm and trophectoderm
340 markers are aberrantly activated.

341

342 **Impaired lumenogenesis in *Esrrb* KO 3D structures**

343 The formative epiblast in the embryo is a polarised epithelium with an apical domain facing a
344 lumen, the proamniotic cavity^{4,6}. Culture of ESCs in 3D allows for epithelialization and self-
345 organisation similarly to the formative epiblast^{4,60,61}. We asked whether the faulty activation of the
346 formative program observed in *Esrrb* KO cells could affect morphogenesis.

347 WT ESCs plated in a hydrogel of extracellular matrix in N2B27 medium formed 3D structures with
348 an apical domain marked by F-ACTIN accumulation and the formative gene PODXL
349 (Supplementary Table 1), as observed in the peri-implantation formative epiblast^{4,60} (Extended
350 Data Fig. 9b, Fig. 8). *Esrrb* KO clones formed fewer structures with a reduced area, but
351 comparable roundness (Extended Data Fig. 9c).

352 We then analysed the polarisation and lumenogenesis of 3D structures. Most WT structures
353 showed a strong and apically localised PODXL signal at 48h, that after 72h and 96h defined a
354 central cavity (Fig. 8a-b). In *Esrrb* KO, the majority of structures failed to form a lumen. We then
355 quantify F-ACTIN intensity along a diameter. In WT cells we found a prominent central peak at
356 48h, separating into two peaks by 96h, indicating the formation of apical domains facing a central
357 lumen (Extended Data Fig. 9d). *Esrrb* KO clones failed to do so. Molecularly, *Esrrb* KO failed to
358 fully activate formative genes, including *Otx2* (Fig. 8c-d and Extended Data Fig. 9e), which has
359 been demonstrated to be both sufficient and required for lumen formation in 3D⁶². Our results
360 reveal that *Esrrb* inactivation causes impaired activation of formative genes and lumenogenesis
361 in 3D structures.

362 *Esrrb* inactivation results in inefficient activation of the key formative gene *Otx2*, under several
363 different experimental conditions (Fig. 5e, 6f, 6e, 7c-d, 8c-d). How does ESRRB regulate *Otx2*?
364 ESRRB might regulate the FGF and TGF-beta signals, which promote transition towards
365 formative state^{6,19,31}. However, *Otx2* levels were unchanged after stimulation or inhibition of both
366 pathways (Extended Data Fig. 10a). *Otx2* expression might be controlled epigenetically. *Otx2*
367 promoter was found bivalent in naive cells (Extended Data Fig. 10b), while an *Otx2* downstream

368 enhancer was bound by ESRRB. ESRRB binding was consolidated in formative cells (Fig. 4c),
369 with a concomitant increase in H3K27ac (Extended Data Fig. 10b), indicating a potential direct
370 regulation of *Otx2* expression by ESRRB.

371 To gain a more comprehensive understanding of how ESRRB regulates *Otx2* and the transition
372 from naive to formative state we turned to computational modelling. We extended a gene
373 regulatory network of naive pluripotency^{17,39,63} by adding formative genes and we inferred
374 interactions between components from RNAseq and ChIP-seq (Fig. 8e and Extended Data Fig.
375 10c). We then defined the naive, formative and committed states (Extended Data Fig. 10d) and
376 constrained the model asking whether it could orderly proceed through them. The model started
377 from the naive state (step 0), it gradually activated formative genes while naive genes were
378 inactivated (step 9, Fig. 8f-g). Finally, all formative genes were inactivated (step 15).

379 The model showed that *Esrrb* KO cells fail to activate some formative genes, including *Otx2*, while
380 naive genes were also inactivated more rapidly (Fig. 8f-g and Extended Data Fig. 10d), in
381 agreement with the faster exit kinetics observed in *Esrrb* KO cells (Fig. 5).

382 We then focussed on how ESRRB regulates the expression of formative genes. ESRRB engages
383 in positive interactions with formative genes already in the naive state, which are maintained until
384 the formative state is reached (Fig. 8g). Thus, *Esrrb* is pre-wired to formative genes in the naive
385 state, in line with ATAC-seq and ESRRB ChIP-seq results. In the absence of *Esrrb* these positive
386 interactions do not take place and the activation of formative genes is impaired (Fig. 8g, bottom
387 panels). Concerning *Otx2* regulation, we detected activating interactions from *Esrrb* and the
388 formative factors Lef1, Utf1 and Dnmt3b. In *Esrrb* KO all those formative genes fail to activate.
389 Thus, *Otx2* expression appears to be controlled by ESRRB, both directly and indirectly.

390

391 Discussion

392 ESC differentiation entails inactivation of naive genes followed by a phase of renovation, named
393 formative pluripotency, in preparation for unbiased germ layer specification^{6,10}. We have identified
394 gene signatures of the formative state that are transiently activated during pluripotency
395 progression (Supplementary Table 1). Subsequently, pluripotent cells express lineage-specific
396 transcription factors and segregation of definitive embryonic lineages occurs. Characterisation of
397 transcriptional and epigenetic profiles of early embryos revealed that in the formative state at E5.5
398 the enhancer landscape of epiblast cells is already set for the specification of neuroectoderm
399 lineage⁶⁴. Not surprisingly, some markers of the formative state (e.g. *Otx2*, *Pou3f1*, *Zic3*) are
400 retained in the neuroectoderm lineage.

401 We also found that activation of formative genes leads to irreversible commitment to differentiate,
402 as reported¹⁰. Of note, “reversibility” indicates the capacity of early differentiated cells to revert to
403 naive pluripotency^{10,40}. This transition could be considered as reprogramming from formative to
404 naive pluripotency. For instance, after 48h of 2iL withdrawal, cells can fully revert, or reprogram,
405 back to the naive state when exposed to 2iL.

406 What orchestrates this ordered progression? What activates formative genes? Our unexpected
407 findings are that ESRRB covers this role. ESRRB was first characterised as a pivotal transcription
408 factor for the maintenance of the naive pluripotency network^{17,22–24,45}, acting downstream of both
409 NANOG and the WNT pathway and its inactivation results in partial loss of naive markers, which
410 is compensated by other naive factors, such as *Nr5a2*⁴⁸. However *in vivo* studies showed that
411 *Esrrb* expression arises in cleavage stage embryos^{65,66} and is maintained in pluripotent cells until
412 the peri-implantation stage⁶², in line with the persistence of ESRRB for up to 48h of *in vitro* ESC
413 differentiation (Fig. 2f). *Esrrb* expression pattern is consistent with a dual role both in the
414 maintenance of naive pluripotency and in activation of formative pluripotency. Our ChIP-

415 sequencing experiments showed that ESRRB binds naive and formative genes in 2iL (Fig. 4).
416 Upon 2iL withdrawal, binding on naive genes decreases while peaks on formative genes are
417 maintained throughout the formative phase.

418 When overexpressed in ESCs, ESRRB ectopically induces both naive and formative gene
419 expression (Fig. 3c-e). Also during resetting of EpiSCs by *Esrrb* overexpression, we noticed
420 robust induction of formative markers *Otx2*, *Dnmt3b* and *Utf1*³⁹. *Esrrb* inactivation leads to
421 impaired induction of formative genes, less robust PGC specification and spontaneous activation
422 of mesendoderm and trophectoderm markers. Furthermore, *Esrrb* KO ESCs failed to form FS
423 cells. Such results clearly endorse the concept of ESRRB as a direct activator of the formative
424 gene program and show that correct activation of the formative program is required for timely and
425 unbiased multilineage differentiation of murine naive pluripotent cells.

426 We investigated the molecular mechanisms associated with dynamic binding of ESRRB in naive
427 and formative cells. ESRRB-bound loci in naive cells were enriched for H3K4me3, H3K27ac and
428 depleted of DNA methylation (Extended Data Fig. 4c), in agreement with a work from Atlasi and
429 collaborators⁴⁷, reporting that 2iL specific enhancers are accessible regions, decorated by
430 H3K27ac and enriched for ESRRB binding. Loci bound by ESRRB only in formative cells are
431 heavily DNA methylated. ESRRB binds DNA-methylated regions, leading to gene activation³⁸ also
432 during reprogramming. Of note, ESRRB binds key chromatin regions during cell divisions to
433 preserve the transcriptional identity of ESCs⁶⁷. This bookmarking activity might also explain the
434 persistent binding of ESRRB on formative genes.

435 Embryos deficient for *Esrrb*, or deficient for its upstream regulator *Nanog*, showed reduced
436 numbers of PGCs^{25,58,68}, which has been imputed to lower production of BMP4 by the
437 extraembryonic ectoderm⁵⁸. However, tetraploid complementation experiments, whereby
438 extraembryonic tissues are provided by wild-type embryos, revealed a reduction in PGCs⁶⁸,

439 indicating that ESRRB must control PGCs number by additional, cell-autonomous mechanisms.
440 We conducted *in vitro* assays in which BMP4 was exogenously provided and saw a reduction in
441 PGCLCs upon *Esrrb* inactivation. Thus, we would propose that the reduction of PGCs in *Esrrb*
442 mutant is due to both reduced BMP signalling and to faulty formative program activation.

443 *Esrrb* null embryos display placental defects at E8.5 and die by E10.5. Epiblast-specific deletion
444 of *Esrrb* or tetraploid complementation allowed to rescue those defects, indicating that ESRRB is
445 a critical regulator of the trophoctoderm lineage⁶⁹⁻⁷¹. Nonetheless, *Esrrb* null embryos were under-
446 represented in a large tetraploid complementation study⁶⁸, suggesting additional *Esrrb*
447 developmental functions in embryonic cells. ESRRB is detected in the epiblast up to E5.0 and
448 *Esrrb* null embryos show growth defects at E6.0⁵⁸. Diapause is a state of metabolic dormancy
449 whereby epiblast cells are held between naive and formative state, and self-organise into
450 polarised rosette-like structures^{41,72}. *Esrrb* null embryos in diapause display a dramatic reduction
451 in the number of epiblast cells, which fail to self-organise⁴¹. Consistently with these *in vivo*
452 observation, *Esrrb* inactivation in a 3D *in vitro* model led to reduced number and size of structures,
453 and impaired self-organisation.

454 We propose that ESRRB confers robustness to epiblast cells transitioning from naive to formative
455 pluripotency. The absence of ESRRB causes alterations (e.g. embryo size and number, PGC
456 number) with partial penetrance. However, when the progression of epiblast cells is delayed or
457 blocked, as in diapause or in FS cells, *Esrrb* becomes strictly required for self-renewal of
458 pluripotent cells. *Esrrb* and *Nr5a2* are two orphan nuclear receptors with overlapping functions,
459 both in totipotent and naive pluripotent cells^{48,66}. Interestingly, *Nr5a2* is expressed both in the
460 naive and formative epiblast and *Nr5a2* null embryos are under-represented and display severe
461 defects at E6.5⁷³ indicating a role for *Nr5a2* in the control of pluripotency progression. It would be
462 therefore interesting to investigate the effect of combined inactivation of *Esrrb* and *Nr5a2*.

463 Reprogramming studies further support a role for ESRRB in multiple embryonic lineages, showing
464 that Esrrb localises preferentially near genes expressed in the epiblast, extraembryonic lineages
465 and PGCs^{38,74}. ESRRB plays also a role, in combination with NR5A2, in the zygotic genome
466 activation of totipotent blastomeres⁶⁶. These observations indicate a multifaceted function of
467 ESRRB in the control of several early embryonic lineages, raising the question of how ESRRB
468 activity can be interpreted in different contexts, possibly thanks to a combination of cell signalling,
469 epigenetic and metabolic regulation.

470

471 **Acknowledgements**

472 We thank Austin Smith for critical reading of the manuscript. This work was supported by
473 Fondazione Telethon Core Grant, Armenise-Harvard Foundation Career Development Award,
474 European Research Council (grant agreement 759154, CellKarma), and the Rita-Levi Montalcini
475 program from MIUR to D.C and M.C. We thank TIGEM NGS core, NEGEDIA and Anna Manfredi
476 for genomic library preparation and sequencing run. Work in J.A.H's laboratory is supported by
477 programme grants from the European Molecular Biology Laboratory (EMBL). Work in H.K.'s group
478 is supported by the ISRAEL SCIENCE FOUNDATION (Grant no. 190/19). G.M.'s laboratory is
479 supported by grants from the Giovanni Armenise–Harvard Foundation, the Telethon Foundation
480 (GJC21157), Microsoft Research and an ERC Starting Grant (MetEpiStem).

481

482 **Author Contributions Statement**

483 G.M. and E.C. conceived the project. E.C., G.M., D.C. and J.A.H. designed the experiments and
484 interpreted the results. E.C. and E.G. performed ESC experiments and analyses. C.M. and D.B.

485 performed molecular analyses of *Esrrb* KO cells. V.P. performed CHIP-PCR experiments.
486 M.Chieragato performed 3D experiments. V.C. performed PGCLC assays. F.P. and A.C.
487 performed bioinformatic analysis of transcriptomic data. M.Cesana performed CHIP-seq
488 experiments. A.G. performed ATAC-seq experiments. M.M. performed CHIP-seq and ATAC-seq
489 analysis. G.M., H.K and E.T. performed computational modelling. E.C., F.P. and J.A.H. prepared
490 figures. G.M. and E.C. wrote the manuscript with help from all authors. G.M., D.C. and J.A.H.
491 secured fundings and supervised the project.

492

493

494

495 **Competing interests Statement**

496 The authors declare no competing interests.

497 **Figure Legends**

498 **Fig. 1: Transcriptional changes associated with irreversible exit from naive pluripotency.**

499 a: Schematic representation of the first stages of exit from the naive state. Upon 2i or 2iL
500 withdrawal, cells transit through a reversible phase before being irreversibly committed to
501 differentiate.

502 b: Top: Morphology and AP staining images after clonal assay of E14 cells cultured in 2iL and
503 after 2iL withdrawal. Bottom: Barplot showing the relative number of AP positive pluripotent
504 colonies after clonal assay of E14 cells cultured both in 2iL (purple) and 2i (green) and after the
505 withdrawal of either 2iL or 2i every 12h for 96h. Mean +/-SD of n=3 independent experiments.
506 Unpaired two-sided t-test '2iL 0' vs '48' p=0.97, '2iL 0' vs '96' p=0.0096. Scale bars= 30 μ m.

507 c: PCA of RNA sequencing data of cells differentiating from 2iL (purple) and from 2i (green).
508 Genes contributing to the first two Principal Components are indicated. N=2 independent
509 biological replicates for each time point, shown as dots.

510 d: Top: Line plot showing expression dynamics of differentially expressed genes during
511 differentiation, grouped by hierarchical clustering based on Pearson Correlation. Grey shades
512 represent a 95% bootstrap confidence interval around mean values. Integration of n=2
513 independent biological replicates for each time point.

514 Pie charts represent the intersection of the gene signatures with published gene sets of mouse
515 embryo development at E4.5, E5.5 and E6.5. Bottom: Heatmaps show the sum of the log₂-scaled
516 normalised expression values of the intersection lists shown in the pie charts, averaged by
517 different time points.

518

519

520 **Fig. 2: Differentiation reversibility is associated with Esrrb expression**

521 a: UCSC genome browser visualisation of normalised ATAC-seq profiles at the indicated loci.

522 Rectangles indicate peaks found only in 2iL (green), only at 48h, both in 2iL and 48h (purple).

523 Integration of n=2 independent biological replicates for each time point.

524 b: Balloon plot summarising the percentage of ATAC peaks containing a given motif, and the

525 associated p-value, at the indicated time points. Peaks on promoters, peaks at 10Kb from TSS

526 and all peaks were analysed and are represented in blue, green and orange respectively.

527 Integration of n=2 independent biological replicates for each time point.

528 c: Balloon plot summarising published ChIP-seq data of ESCs cultured in Serum+LIF from the

529 Codex compendium³⁷. The size of each balloon indicates the fold enrichment, the colour indicates

530 the statistical significance.

531 d: left: Bar plot showing the number of AP positive colonies after clonal assay performed on cells

532 overexpressing a pool of pluripotency genes and maintained in 2iL (grey bars) or differentiated

533 for 96h (blue bars). Cells overexpressing an empty vector were used as control (empty). Bars

534 indicate mean +/-SD of n=3 independent experiments, shown as dots. Right: Bar plot showing

535 enrichment of genomic integrations of 8 naive genes in cells differentiated for 96h and plated for

536 clonal assay compared to cells in 2iL. Bars indicate mean +/-SD of n=3 independent experiments,

537 shown as dots.

538 e: Representative images of clonal assay followed by Alkaline Phosphatase staining of cells

539 overexpressing an empty vector or pluripotency factors, either maintained in 2iL or differentiated

540 for 96h. N=2 independent experiments, quantified in Extended Data Fig. 2g.

541 f: Immunostaining for ESRRB (green) in E14 cells cultured in 2iL or differentiated for 48, 96 or

542 120h (48, 96 120) or after reinduction with 2iL for 24h (48+24 and 96+24). Nuclei were identified

543 by DAPI staining (blue). Scale bar: 25µm. N=3 independent experiments, quantified in Extended

544 Data Fig. 3c.

545

546 **Fig. 3: Esrrb promotes the expression of formative genes**

547 a: Schematic representation of E14 cells transfected with an inducible Esrrb-Ires-Venus vector
548 (EIV) and differentiated for 96h with or without Doxycycline (DOX) treatment. Cells were sorted
549 for presence or absence of Venus expression (EIV+ and EIV- respectively) and further
550 characterised.

551 b: Left: Representative images of Alkaline phosphatase staining after clonal assay of cells
552 expressing EIV or an inducible Empty vector (iEmpty), cultured in 2iL or without 2iL for 96h (96),
553 in the presence of DOX. Right: Barplot showing number of AP positive colonies in cells expressing
554 EIV or iEmpty, cultured in 2iL or without 2iL for 96h, in the presence or absence of DOX (+D or -
555 D). Mean +/-SD of 4 biological replicates. Two-sided unpaired Student t-test.

556 c: Heatmaps showing mean-scaled normalised expression levels, measured by RNA-seq, of
557 selected naive, formative and committed genes in E14 cells expressing EIV cultured in 2iL or
558 differentiated for 96h in the presence or absence of DOX (96-DOX or 96+DOX respectively).
559 Integration of n=2 independent experiments.

560 d: Expression levels of selected naive and formative genes measured by qPCR in cells treated
561 as described in Fig. 3b. Mean of n=2 independent experiments. Expression of naive genes is
562 normalised to iEmpty cells kept in 2iL -D. Formative genes are normalised to E14 cells
563 differentiated for 48h.

564 e: Scatter plot showing transcriptome analysis of E14 cells expressing EIV cells differentiated for
565 96h in N2B27 with or without DOX. Down-regulated ($\text{Log}_2\text{FC} < -1$ and $p\text{-value} < 0.01$) and Up-
566 regulated ($\text{Log}_2\text{FC} > 1$ and $p\text{-value} < 0.01$) genes are plotted on the left or right part of the panel
567 respectively. The Y-axis indicates the mean expression on a log scale. Genes belonging to the 6
568 genes signatures described are represented by coloured dots. Selected genes are highlighted.
569 Integration of n=2 independent experiments.

570 **Fig. 4: Esrrb promotes the expression of formative genes**

571 a,b: ChIP-seq analysis of E14 cells cultured in 2iL and differentiated for 48h and 96h in N2B27.

572 Time points are colour-coded in blue (2iL), cyan (48h) and yellow (96h). N=1 biological replicate.

573 a: Venn diagram showing the intersection of significant ESSRB peaks for each given time point

574 obtained by ChIP-seq analysis of E14 cells cultured in 2iL and differentiated for 48h and 96h in

575 N2B27.

576 b: Binding heatmaps displaying the read coverage density of ESSRB peaks along with average

577 intensity. Peaks are grouped by the presence in one or multiple time points. For example, the “2iL

578 - 48” group contains peaks found both in 2iL and after 48h of differentiation.

579 c: Representative genome browser snapshots of selected gene loci bound by ESSRB in each

580 given time point. Both reads distributions as line plots and peak intervals are displayed. N=1

581 biological replicate.

582 **Fig. 5: Esrrb coordinates the activation of naive and formative programs.**

583 a: Left: Bar plot showing number of AP positive colonies after clonal assay of E14 cells transfected
584 with a non-targeting control siRNA (siCo, dark grey), siGFP (light grey) or si*Esrrb* (blue) and
585 cultured in 2iL or differentiated for 24h and 48h. Centre and Right: Expression analysis by qPCR
586 of *Esrrb* and *Tfcp2l1* genes in E14 cells transfected with siCo, siGFP and si*Esrrb* and
587 differentiated for 24h or 48h. Bars indicate mean +/-SD of n=4 independent experiments, shown
588 as dots. The 24h sample was analysed in n=3 experiments.

589 b: Top: Immunoblot of clonal lines derived from E14 cell population stably expressing Cas9 and
590 transfected with 2 gRNAs flanking *Esrrb* DNA-binding region. Three *Esrrb* KO clones were chosen
591 (KO1, KO2, KO3). GAPDH was used as a loading control. Bottom: Barplot showing number of
592 AP positive colonies after clonal assay of E14 cells (WT) and 3 *Esrrb* KO clonal lines cultured in
593 2iL and after 24h, 48h and 72h of differentiation. Mean +/-SD from n=3 independent experiments,
594 shown as dots.

595 c: PCA of RNA sequencing data obtained from E14 (WT) and 3 *Esrrb* KO clones cultured in 2iL
596 and after 24h, 48h and 72h of differentiation. N=2 biological replicates for each data point, shown
597 as dots.

598 d: Transcriptome analysis of *Esrrb* KO cells cultured in 2iL and after 24h, 48h and 72h of
599 differentiation in N2B27. Down-regulated and Up-regulated genes (P-value <0.05, FC >1 or <-1,
600 compared to WT) are plotted on the left or right part of each panel. Genes belonging to the 6
601 genes signatures are highlighted with coloured dots. Integration of n=2 biological replicates for
602 each cell line. Mean of the 3 independent *Esrrb* KO clones.

603 e: Heatmaps showing mean-scaled normalised expression levels, measured by RNA-seq, of
604 selected naive, formative and committed genes in WT and *Esrrb* KO clones. Integration of n=2
605 biological replicates for each cell line. Mean of the 3 independent *Esrrb* KO clones.

606 **Fig. 6: Esrrb is required for generation of FS cells**

607 a: Experimental strategy used to induce *Esrrb* specifically at the time of activation of the formative
608 program.

609 b: Relative expression of *Esrrb* and selected formative genes measured by qPCR in Conditional
610 *Esrrb* cells differentiated for 72h and treated with a pulse of DOX between 24 and 48h. *Esrrb* KO
611 clones expressing an inducible Empty vector (iEmpty) served as controls. Bars indicate mean +/-
612 SD of n=5 independent experiments for *Tcf15* and n=3 for all other markers, shown as dots.

613 c: Experimental strategy used to remove *Esrrb* at the time of activation of the formative program.

614 d: Immunostaining for ESRRB in WT cells in 2iL and in Conditional *Esrrb* cells cultured either in
615 the presence or absence of DOX for 48h. *Esrrb* KO cells expressing an Empty vector served as
616 negative controls. Scale bar= 25 μ m. Representative images from 3 independent experiments.

617 e: Volcano plot depicting DEGs (adjusted P-value<0.05) in *Esrrb* conditional cells kept without
618 DOX vs WT cells after 48h of differentiation. Genes belonging to the 6 gene signatures are
619 highlighted with coloured dots. Total number of Formative early and Formative late genes down
620 and up-regulated in Conditional *Esrrb* cells are coloured in green and purple in the bottom corners.
621 Integration of n=5 independent experiments.

622 f: RNAseq analysis in *Esrrb conditional cells* withdrawn of 2iL and DOX for 48h (3rd bar). WT cells
623 expressing an inducible Empty vector (iEmpty) cultured either in 2iL or differentiated for 48h were
624 used as controls (1st and 2nd bar). Bars indicate mean +/-SD of n=5 independent experiments,
625 shown as dots.

626 g: Representative images of WT and *Esrrb* KO cells cultured in AloXR for 3 or 9 passages. Scale
627 bar: 25 μ m. *Esrrb* KO cells collapsed between passage 4 and 6 in n=3 independent attempts.

628 h: Line plots showing gene expression during FS differentiation. Mean +/- SD of n=4 independent
629 biological replicates, shown as dots.

630 **Fig. 7: Differentiation towards PGCs is impaired by loss of *Esrrb***

631 a: Left: Quantification of the percentage of *Stella*-GFP positive PGCLC at day3 (early) and day5
632 (late) of independent WT (grey) and *Esrrb* KO SGET lines (blue) (n=3 independent KO clones
633 and matching WT controls, shown as dots). Bar indicates mean value. p-values indicate two-sided
634 unpaired t-test. Right: Flow cytometry plots showing impaired induction of PGCLC in *Esrrb*-
635 knockout (KO) cells. Percentages of *Stella*+ PGCLC are shown in representative plots of three
636 independent WT and KO lines.

637 b: PCA showing the developmental trajectory of independent *Esrrb* KO (blue) and matched-WT
638 (grey) SGET lines during induction of PGCLC, based on the global transcriptome of n=3
639 independent KO clones and matching WT controls, shown as dots.

640 c: Volcano plots depicting DEGs in *Esrrb* KO EpiLC, d3 and d5 PGCLC. Down-regulated and Up-
641 regulated genes (adjusted p-value <0.05) are plotted on the left or right part of each panel
642 respectively. Formative -early and -late and PGC -early and -late signatures (genesets) are
643 highlighted with coloured dots indicating general shifts in activity of specific programs. Integration
644 of n=3 independent KO clones and matching WT controls.

645 d: Barplots showing gene expression of selected genes in independent WT (grey) and *Esrrb* KO
646 lines (blue) at EpiLC, d3 and d5 PGCLC stages. Integration of n=3 independent KO clones and
647 matching WT controls. See also Extended Data Fig. 8.

648 **Fig. 8: Impaired lumenogenesis in *Esrrb* KO 3D structures**

649 a: Representative images of WT and *Esrrb* KO cells cultured in N2B27 medium in matrigel for
650 96h. Nuclei were identified by DAPI staining (blue). Left: Filamentous (F) ACTIN was labelled by
651 Phalloidin staining. Right: Immunostaining for PODXL. Scale bars: 30µm. Similar results were
652 obtained with 2 *Esrrb* KO clones in n=2 independent experiments.

653 b: Barplot showing quantification of number of structures with an apically localised PODXL
654 (polarised), with a defined central cavity (lumen) or negative for PODXL (negative) in WT and
655 *Esrrb* KO cells cultured in N2B27 medium in matrigel for 48h, 72h or 96h. Bars indicate mean of
656 n=2 independent experiments, shown as dots.

657 c: Heatmaps showing mean normalised expression measured by qPCR of the naive gene *Tfcp2l1*
658 and formative genes in WT and *Esrrb* KO cells in 2iL or cultured in N2B27 in matrigel for 24h,
659 48h, 72h or 96h. Mean of n=3 independent experiments. Stars indicate p-value<0.05 calculated
660 by two-sided unpaired Student t-test.

661 d: Representative images of immunostaining for OTX2 in WT and *Esrrb* KO cells cultured in
662 N2B27 in matrigel for 48h. Scale bar: 30µm. Similar results were obtained with 2 *Esrrb* KO clones
663 in n=2 independent experiments.

664 e: Heatmap showing Pearson's correlation of naive, core and formative genes, obtained from
665 RNAseq data of 2iL withdrawal (Fig. 1c-d)

666 f: Left, trajectory followed by WT ESCs from the naive (step 0) to formative (step 9) to committed
667 state (step 14) in a representative model. Right, trajectory followed by *Esrrb* KO cells.

668 g: Network representation of the model used to calculate the trajectories shown in f. Black solid
669 lines indicate interactions from active components. Grey lines indicate interactions not present,
670 as they emanate from inactive components. Positive regulations are indicated by a black arrow,
671 negative regulations are indicated by a black circle-headed line.

672 **References**

- 673 1. Boroviak, T., Loos, R., Bertone, P., Smith, A. & Nichols, J. The ability of inner-cell-mass
674 cells to self-renew as embryonic stem cells is acquired following epiblast specification. *Nat.*
675 *Cell Biol.* **16**, 516–528 (2014).
- 676 2. Kinoshita, M. & Smith, A. Pluripotency Deconstructed. *Dev. Growth Differ.* **60**, 44–52 (2018).
- 677 3. Morgani, S., Nichols, J. & Hadjantonakis, A.-K. The many faces of Pluripotency: in vitro
678 adaptations of a continuum of in vivo states. *BMC Dev. Biol.* **17**, 7 (2017).
- 679 4. Bedzhov, I. & Zernicka-Goetz, M. Self-organizing properties of mouse pluripotent cells
680 initiate morphogenesis upon implantation. *Cell* **156**, 1032–1044 (2014).
- 681 5. Endoh, M. & Niwa, H. Stepwise pluripotency transitions in mouse stem cells. *EMBO Rep.*
682 **23**, e55010 (2022).
- 683 6. Smith, A. Formative pluripotency: the executive phase in a developmental continuum.
684 *Development* **144**, 365–373 (2017).
- 685 7. Pera, M. F. & Rossant, J. The exploration of pluripotency space: Charting cell state
686 transitions in peri-implantation development. *Cell Stem Cell* **28**, 1896–1906 (2021).
- 687 8. Buecker, C. *et al.* Reorganization of enhancer patterns in transition from naive to primed
688 pluripotency. *Cell Stem Cell* **14**, 838–853 (2014).
- 689 9. Hayashi, K., Ohta, H., Kurimoto, K., Aramaki, S. & Saitou, M. Reconstitution of the mouse
690 germ cell specification pathway in culture by pluripotent stem cells. *Cell* **146**, 519–532
691 (2011).
- 692 10. Kalkan, T. *et al.* Tracking the embryonic stem cell transition from ground state pluripotency.
693 *Dev. Camb. Engl.* **144**, 1221–1234 (2017).
- 694 11. Meissner, A. Epigenetic modifications in pluripotent and differentiated cells. *Nat. Biotechnol.*
695 **28**, 1079–1088 (2010).

- 696 12. Evans, M. J. & Kaufman, M. H. Establishment in culture of pluripotential cells from mouse
697 embryos. *Nature* **292**, 154–156 (1981).
- 698 13. Martin, G. R. Isolation of a pluripotent cell line from early mouse embryos cultured in
699 medium conditioned by teratocarcinoma stem cells. *Proc. Natl. Acad. Sci. U. S. A.* **78**,
700 7634–7638 (1981).
- 701 14. Smith, A. G. *et al.* Inhibition of pluripotential embryonic stem cell differentiation by purified
702 polypeptides. *Nature* **336**, 688–690 (1988).
- 703 15. Williams, R. L. *et al.* Myeloid leukaemia inhibitory factor maintains the developmental
704 potential of embryonic stem cells. *Nature* **336**, 684–687 (1988).
- 705 16. Ying, Q.-L. *et al.* The ground state of embryonic stem cell self-renewal. *Nature* **453**, 519–
706 523 (2008).
- 707 17. Dunn, S.-J., Martello, G., Yordanov, B., Emmott, S. & Smith, A. G. Defining an essential
708 transcription factor program for naïve pluripotency. *Science* **344**, 1156–1160 (2014).
- 709 18. Wray, J., Kalkan, T. & Smith, A. G. The ground state of pluripotency. *Biochem. Soc. Trans.*
710 **38**, 1027–1032 (2010).
- 711 19. Kinoshita, M. *et al.* Capture of Mouse and Human Stem Cells with Features of Formative
712 Pluripotency. *Cell Stem Cell* **28**, 453-471.e8 (2021).
- 713 20. Betschinger, J. *et al.* Exit from Pluripotency Is Gated by Intracellular Redistribution of the
714 bHLH Transcription Factor Tfe3. *Cell* **153**, 335–347 (2013).
- 715 21. Ying, Q.-L., Stavridis, M., Griffiths, D., Li, M. & Smith, A. Conversion of embryonic stem cells
716 into neuroectodermal precursors in adherent monoculture. *Nat. Biotechnol.* **21**, 183–186
717 (2003).
- 718 22. Festuccia, N. *et al.* Esrrb is a direct Nanog target gene that can substitute for Nanog
719 function in pluripotent cells. *Cell Stem Cell* **11**, 477–490 (2012).
- 720 23. Ivanova, N. *et al.* Dissecting self-renewal in stem cells with RNA interference. *Nature* **442**,
721 533–538 (2006).

- 722 24. Martello, G. *et al.* Esrrb is a pivotal target of the Gsk3/Tcf3 axis regulating embryonic stem
723 cell self-renewal. *Cell Stem Cell* **11**, 491–504 (2012).
- 724 25. Zhang, M. *et al.* Esrrb Complementation Rescues Development of Nanog-Null Germ Cells.
725 *Cell Rep.* **22**, 332–339 (2018).
- 726 26. Qiu, D. *et al.* Klf2 and Tfcp2l1, Two Wnt/ β -Catenin Targets, Act Synergistically to Induce
727 and Maintain Naive Pluripotency. *Stem Cell Rep.* **5**, 314–322 (2015).
- 728 27. Yang, P. *et al.* Multi-omic Profiling Reveals Dynamics of the Phased Progression of
729 Pluripotency. *Cell Syst.* **8**, 427-445.e10 (2019).
- 730 28. Kalkan, T. *et al.* Complementary Activity of ETV5, RBPJ, and TCF3 Drives Formative
731 Transition from Naive Pluripotency. *Cell Stem Cell* **24**, 785-801.e7 (2019).
- 732 29. Lackner, A. *et al.* Cooperative genetic networks drive embryonic stem cell transition from
733 naive to formative pluripotency. *EMBO J.* **40**, e105776 (2021).
- 734 30. Acampora, D. *et al.* Loss of the Otx2-Binding Site in the Nanog Promoter Affects the
735 Integrity of Embryonic Stem Cell Subtypes and Specification of Inner Cell Mass-Derived
736 Epiblast. *Cell Rep.* **15**, 2651–2664 (2016).
- 737 31. Mulas, C., Kalkan, T. & Smith, A. NODAL Secures Pluripotency upon Embryonic Stem Cell
738 Progression from the Ground State. *Stem Cell Rep.* **9**, 77–91 (2017).
- 739 32. Mohammed, H. *et al.* Single-Cell Landscape of Transcriptional Heterogeneity and Cell Fate
740 Decisions during Mouse Early Gastrulation. *Cell Rep.* **20**, 1215–1228 (2017).
- 741 33. Chambers, I. *et al.* Nanog safeguards pluripotency and mediates germline development.
742 *Nature* **450**, 1230–1234 (2007).
- 743 34. Hayashi, K., de Sousa Lopes, S. M. C., Tang, F., Lao, K. & Surani, M. A. Dynamic
744 equilibrium and heterogeneity of mouse pluripotent stem cells with distinct functional and
745 epigenetic states. *Cell Stem Cell* **3**, 391–401 (2008).
- 746 35. Kolodziejczyk, A. A. *et al.* Single Cell RNA-Sequencing of Pluripotent States Unlocks
747 Modular Transcriptional Variation. *Cell Stem Cell* **17**, 471–485 (2015).

- 748 36. Papatsenko, D. *et al.* Single-Cell Analyses of ESCs Reveal Alternative Pluripotent Cell
749 States and Molecular Mechanisms that Control Self-Renewal. *Stem Cell Rep.* **5**, 207–220
750 (2015).
- 751 37. Sánchez-Castillo, M. *et al.* CODEX: a next-generation sequencing experiment database for
752 the haematopoietic and embryonic stem cell communities. *Nucleic Acids Res.* **43**, D1117-
753 1123 (2015).
- 754 38. Adachi, K. *et al.* Esrrb Unlocks Silenced Enhancers for Reprogramming to Naive
755 Pluripotency. *Cell Stem Cell* **23**, 266-275.e6 (2018).
- 756 39. Dunn, S.-J., Li, M. A., Carbognin, E., Smith, A. & Martello, G. A common molecular logic
757 determines embryonic stem cell self-renewal and reprogramming. *EMBO J.* **38**, (2019).
- 758 40. Festuccia, N. *et al.* Esrrb extinction triggers dismantling of naïve pluripotency and marks
759 commitment to differentiation. *EMBO J.* **37**, e95476 (2018).
- 760 41. Fan, R. *et al.* Wnt/Beta-catenin/Esrrb signalling controls the tissue-scale reorganization and
761 maintenance of the pluripotent lineage during murine embryonic diapause. *Nat. Commun.*
762 **11**, 5499 (2020).
- 763 42. Shy, B. R. *et al.* Regulation of Tcf7l1 DNA binding and protein stability as principal
764 mechanisms of Wnt/ β -catenin signaling. *Cell Rep.* **4**, 1–9 (2013).
- 765 43. Wray, J. *et al.* Inhibition of glycogen synthase kinase-3 alleviates Tcf3 repression of the
766 pluripotency network and increases embryonic stem cell resistance to differentiation. *Nat.*
767 *Cell Biol.* **13**, 838–845 (2011).
- 768 44. Martello, G., Bertone, P. & Smith, A. Identification of the missing pluripotency mediator
769 downstream of leukaemia inhibitory factor. *EMBO J.* **32**, 2561–2574 (2013).
- 770 45. Zhang, X., Zhang, J., Wang, T., Esteban, M. A. & Pei, D. Esrrb activates Oct4 transcription
771 and sustains self-renewal and pluripotency in embryonic stem cells. *J. Biol. Chem.* **283**,
772 35825–35833 (2008).

- 773 46. Sone, M. *et al.* Hybrid Cellular Metabolism Coordinated by Zic3 and Esrrb Synergistically
774 Enhances Induction of Naive Pluripotency. *Cell Metab.* **25**, 1103-1117.e6 (2017).
- 775 47. Atlasi, Y. *et al.* Epigenetic modulation of a hardwired 3D chromatin landscape in two naive
776 states of pluripotency. *Nat. Cell Biol.* **21**, 568–578 (2019).
- 777 48. Festuccia, N., Owens, N., Chervova, A., Dubois, A. & Navarro, P. The combined action of
778 Esrrb and Nr5a2 is essential for murine naïve pluripotency. *Dev. Camb. Engl.* **148**,
779 dev199604 (2021).
- 780 49. Kojima, Y. *et al.* The transcriptional and functional properties of mouse epiblast stem cells
781 resemble the anterior primitive streak. *Cell Stem Cell* **14**, 107–120 (2014).
- 782 50. Tsakiridis, A. *et al.* Distinct Wnt-driven primitive streak-like populations reflect in vivo lineage
783 precursors. *Dev. Camb. Engl.* **141**, 1209–1221 (2014).
- 784 51. Nichols, J. & Smith, A. Naive and primed pluripotent states. *Cell Stem Cell* **4**, 487–492
785 (2009).
- 786 52. Brons, I. G. M. *et al.* Derivation of pluripotent epiblast stem cells from mammalian embryos.
787 *Nature* **448**, 191–195 (2007).
- 788 53. Guo, G. *et al.* Klf4 reverts developmentally programmed restriction of ground state
789 pluripotency. *Dev. Camb. Engl.* **136**, 1063–1069 (2009).
- 790 54. Tesar, P. J. *et al.* New cell lines from mouse epiblast share defining features with human
791 embryonic stem cells. *Nature* **448**, 196–199 (2007).
- 792 55. Sumi, T., Oki, S., Kitajima, K. & Meno, C. Epiblast ground state is controlled by canonical
793 Wnt/ β -catenin signaling in the postimplantation mouse embryo and epiblast stem cells. *PLoS*
794 *One* **8**, e63378 (2013).
- 795 56. Magnúsdóttir, E. & Surani, M. A. How to make a primordial germ cell. *Dev. Camb. Engl.*
796 **141**, 245–252 (2014).
- 797 57. Hackett, J. A. *et al.* Tracing the transitions from pluripotency to germ cell fate with CRISPR
798 screening. *Nat. Commun.* **9**, 4292 (2018).

- 799 58. Okamura, E. *et al.* Esrrb function is required for proper primordial germ cell development in
800 presomite stage mouse embryos. *Dev. Biol.* **455**, 382–392 (2019).
- 801 59. Miyazono, K., Maeda, S. & Imamura, T. BMP receptor signaling: Transcriptional targets,
802 regulation of signals, and signaling cross-talk. *Cytokine Growth Factor Rev.* **16**, 251–263
803 (2005).
- 804 60. Shahbazi, M. N. *et al.* Pluripotent state transitions coordinate morphogenesis in mouse and
805 human embryos. *Nature* **552**, 239–243 (2017).
- 806 61. Wang, X. *et al.* Formative pluripotent stem cells show features of epiblast cells poised for
807 gastrulation. *Cell Res.* **31**, 526–541 (2021).
- 808 62. Neagu, A. *et al.* In vitro capture and characterization of embryonic rosette-stage
809 pluripotency between naive and primed states. *Nat. Cell Biol.* **22**, 534–545 (2020).
- 810 63. Yordanov, B. *et al.* A Method to Identify and Analyze Biological Programs through
811 Automated Reasoning. *NPJ Syst. Biol. Appl.* **2**, 16010- (2016).
- 812 64. Argelaguet, R. *et al.* Multi-omics profiling of mouse gastrulation at single-cell resolution.
813 *Nature* **576**, 487–491 (2019).
- 814 65. Boroviak, T. *et al.* Lineage-Specific Profiling Delineates the Emergence and Progression of
815 Naive Pluripotency in Mammalian Embryogenesis. *Dev. Cell* **35**, 366–382 (2015).
- 816 66. Gassler, J. *et al.* Zygotic genome activation by the totipotency pioneer factor Nr5a2. *Science*
817 **378**, 1305–1315 (2022).
- 818 67. Festuccia, N. *et al.* Mitotic binding of Esrrb marks key regulatory regions of the pluripotency
819 network. *Nat. Cell Biol.* **18**, 1139–1148 (2016).
- 820 68. Mitsunaga, K. *et al.* Loss of PGC-specific expression of the orphan nuclear receptor ERR-
821 beta results in reduction of germ cell number in mouse embryos. *Mech. Dev.* **121**, 237–246
822 (2004).

- 823 69. Byerly, M. S. *et al.* Estrogen-related receptor β deletion modulates whole-body energy
824 balance via estrogen-related receptor γ and attenuates neuropeptide Y gene expression.
825 *Eur. J. Neurosci.* **37**, 1033–1047 (2013).
- 826 70. Latos, P. A. *et al.* Fgf and Esrrb integrate epigenetic and transcriptional networks that
827 regulate self-renewal of trophoblast stem cells. *Nat. Commun.* **6**, 7776 (2015).
- 828 71. Luo, J. *et al.* Placental abnormalities in mouse embryos lacking the orphan nuclear receptor
829 ERR-beta. *Nature* **388**, 778–782 (1997).
- 830 72. Bulut-Karslioglu, A. *et al.* Inhibition of mTOR induces a paused pluripotent state. *Nature*
831 **540**, 119–123 (2016).
- 832 73. Gu, P. *et al.* Orphan nuclear receptor LRH-1 is required to maintain Oct4 expression at the
833 epiblast stage of embryonic development. *Mol. Cell. Biol.* **25**, 3492–3505 (2005).
- 834 74. Benchetrit, H. *et al.* Direct Induction of the Three Pre-implantation Blastocyst Cell Types
835 from Fibroblasts. *Cell Stem Cell* **24**, 983-994.e7 (2019).
- 836

837 **Methods**

838 **ESCs culture**

839 All cell lines were routinely cultured on plates coated with 0.2% Gelatin (Sigma-Aldrich, G1890)
840 in N2B27 medium (DMEM-F12 and Neurobasal at 1:1 ratio (Life Technologies), 1X N2
841 Supplement (Life Technologies), 1X B27 Supplement (Life Technologies), 2mM L-Glutamine (Life
842 Technologies), 0.1mM 2-mercaptoethanol) with the addition of 2iL (3uM CHIR99021 (Axon), 1uM
843 PD0325901 (Axon), 1uM LIF (Qkine)). Media was replaced every other day and cells were
844 passaged every 3 days at 1×10^4 cells/cm² density, following dissociation with Accutase (Life
845 Technologies, cat. A11110501). E14IVc mouse ESCs were kindly provided by Austin Smith's
846 laboratory⁷⁵. Esrrb fl/fl and Esrrb^{-/-} cells (Extended Data Fig.5a) were provided by Hitoshi Niwa's
847 laboratory²⁴.

848

849 **Monolayer differentiation, clonal assay, ESCs to EpiSCs differentiation and FS cells** 850 **generation**

851 For monolayer differentiation experiments, 5000 cells/12 well were plated at single cell density on
852 0.2% Gelatin coated plates in N2B27 medium with 2iL.

853 For clonal assays, cells were dissociated at indicated time points and 300 cells/12 well were plated
854 at single cell density on 0.2% Gelatin coated plates in KSR medium (GMEM (Sigma Aldrich,
855 G5154) supplemented with 10% KnockOut Serum Replacement (Life Technologies), 2% FBS
856 (Sigma Aldrich), MEM non-essential amino acids (Life Technologies), 1mM Sodium Pyruvate (Life
857 Technologies), 2mM L-Glutamine, 0.1mM 2-mercaptoethanol) with 2iL. After 4 days, cells were
858 fixed and stained for Alkaline Phosphatase (AP) (Sigma, 86R 1KT) according to manufacturer
859 instructions. Plates were scanned with Epson Scanner and AP positive colonies were scored
860 manually.

861 For ESCs to EpiSCs differentiation, 35000 cells/12 well were plated on fibronectin (Sigma Aldrich
862 FC010)-coated plates in N2B27 medium supplemented with 20 ng/ml ActivinA (Qkine), 12.5 ng/ml
863 FGF2 (Qkine) and 1uM XAV939 (Axon Medchem). After three days cells were passaged in
864 clumps using Accutase and were subsequently passaged every two days in a ratio of 1:5 or 1:10
865 depending on the cell density. ROCK inhibitor (Y27632 dihydrochloride, Axon Medchem) was
866 added one hour before detaching the cells and for 6-12 hours after plating.

867 For Formative Stem (FS) cells generation, mouse ESCs were plated at standard density in
868 fibronectin-coated well in N2B27 medium. The next day, medium was changed to AloXR (3 ng/ml
869 of activin A, 2 μ M XAV, 1.0 μ M BMS439 in N2B27 medium). The next day cells were dissociated
870 into clumps with Accutase and plated at higher density than established cultures (1/5 ratio).
871 Medium was changed every day and cells split every other day.

872

873 **3D structures generation**

874 10000 mouse ESCs were resuspended in a 20uL drop of Matrigel (Corning, 356231) in a 8-well
875 chamber slide (Life Technologies, 154534PK) and placed at 37° for 3 minutes to allow
876 polymerisation. Each well was then filled with 300uL of N2B27 to allow 3D structures formation.
877 Medium was changed after 2 days.

878

879 **RNA extraction, cDNA synthesis and quantitative PCR**

880 Total RNA was isolated using Total RNA Purification kit (Norgen Bioteck, cat.37500) and
881 complementary DNA was synthesised using M-MLV Reverse Transcriptase (Life Technologies,
882 cat.28025-013) and random hexamers. qPCR was performed with SYBR Green Master mix
883 (Bioline BIO-94020). Expression levels were normalised to Gapdh. See also Supplementary
884 Table 4 for primer details.

885

886 **RNA-sequencing library preparation and sequencing for ESCs experiments**

887 Total RNA was quantified using the Qubit 2.0 fluorimetric Assay (Thermo Fisher Scientific).
888 Libraries were prepared from 250 ng of total RNA using the 3'DGE mRNA-seq sequencing service
889 (TIGEM NGS Core) which included library preparation, quality assessment, and sequencing on a
890 NovaSeq 6000 sequencing system using a single-end, 100-cycle strategy (Illumina Inc.).

891

892 **RNA-sequencing data pre-processing and analysis for ESCs experiments**

893 Illumina NovaSeq base call (BCL) files were converted in fastq file through bcl2fastq
894 ([http://emea.support.illumina.com/content/dam/illumina-](http://emea.support.illumina.com/content/dam/illumina-support/documents/documentation/software_documentation/bcl2fastq/bcl2fastq2-v2-20-software-guide-15051736-03.pdf)
895 [support/documents/documentation/software_documentation/bcl2fastq/bcl2fastq2-v2-20-](http://emea.support.illumina.com/content/dam/illumina-support/documents/documentation/software_documentation/bcl2fastq/bcl2fastq2-v2-20-software-guide-15051736-03.pdf)
896 [software-guide-15051736-03.pdf](http://emea.support.illumina.com/content/dam/illumina-support/documents/documentation/software_documentation/bcl2fastq/bcl2fastq2-v2-20-software-guide-15051736-03.pdf) - (v2.20.0.422). The raw data were analyzed by Next
897 Generation Diagnostic srl proprietary 3'DGE mRNA-seq pipeline (v2.0) which involves a cleaning
898 step by quality filtering and trimming ([https://jgi.doe.gov/data-and-tools/bbtools/bb-tools-user-](https://jgi.doe.gov/data-and-tools/bbtools/bb-tools-user-guide/usage-guide/)
899 [guide/usage-guide/](https://jgi.doe.gov/data-and-tools/bbtools/bb-tools-user-guide/usage-guide/) - bbmap suite 37.31), alignment to mm10 reference genome assembly⁷⁶, and
900 counting by gene⁷⁷ using mm10 Ensembl assembly (release 93). Differential expression analyses
901 were performed using edgeR⁷⁸ on genes having more than 1 CPM in more than the minimum
902 number of samples belonging to one condition minus 1 and less than 20% of multi-mapping reads,
903 simultaneously.

904 PCA was performed on $\log_2(\text{CPM})$, after filtering out genes with average raw counts across the
905 dataset less than 5, using *prcomp* function from R (v. 4.2).

906 Time course differential expression analysis was performed through Gaussian process regression
907 ⁷⁹after voom⁸⁰ transformation of $\log_2(\text{CPM})$. Genes with log-ratio of marginal likelihood greater
908 than 5 were considered differentially expressed and used for clustering analysis. Gene clusters
909 were first defined by dividing genes in three groups, based on their maximum expression
910 (maximum at time 0, between 24 and 72 hours and between 84 and 96 hours respectively). A
911 hierarchical clustering based on Pearson correlation, performed on the aforementioned groups,

912 allowed the identification of the 6 gene signatures (naive early, naive late, formative early,
913 formative late, committed early, committed late) used in this study.
914 Pathway and gene sets enrichment analysis was conducted using the R package Enrichr(v. 3.0)
915 on KEGG and Wikipathways (wikipathways.org) databases.
916 To perform the enrichment of cell-stress (GO:0033554) and apoptosis (KEGG) gene signatures
917 in KO experiments, we used pre-ranked Gene Set Enrichment Analysis (GSEA) from *fgsea* (v
918 1.14.0) R package. Pre-ranked lists for each time-point or passage were generated by multiplying
919 \log_2 fold change (L2FC) and false discovery rate (FDR) values as obtained by the differential
920 expression analysis between KO and WT samples^{81–85}.

921

922 **Generation of Overexpression (O/E) ESCs**

923 For DNA transfection, Lipofectamine 2000 (Life Technologies, cat. 11668019) was used and
924 reverse transfection was performed. Briefly, cells were dissociated with Accutase and
925 resuspended in N2B27 +2iL. 1.5×10^5 cells were mixed with 750uL 2iL, 3uL Lipofectamine 2000
926 (Life Technologies), 125uL of Optimem, 500ng of transposon and 500ng of transposase and
927 plated in a Gelatin coated well of a 12 well plate. Media was changed to 2iL after overnight
928 incubation.

929

930 **siRNA transfection**

931 For siRNA transfection, E14 cells were dissociated and resuspended in N2B27 + 2iL. 25×10^3 cells
932 were mixed with 400uL 2iL, 1.5 uL Lipofectamine 2000 (Life Technologies), 100uL of Optimem
933 (Life Technologies), siRNA at a final concentration of 40nM and plated in a Gelatin coated well of
934 a 12 well plate. Media was changed to 2iL after overnight incubation. 2iL was withdrawn for
935 differentiation assay after 7h and replaced with N2B27 medium.

936

937 **Generation of Knock-out ESCs using CRISPR-Cas9-mediated mutagenesis**

938 gRNAs were cloned into U6 vector. Two gRNAs targeting different exons of a gene were co-
939 transfected into E14 ESCs stably expressing Cas9, using Lipofectamine 2000 (Life Technologies).
940 Transfected cells were selected using G418/Neomycin (50 ug/ml). Clones were picked and
941 expanded in 2iL. gRNA sequences are listed in Supplementary Table 5.

942 **Immunofluorescence staining and Image Analysis**

943 Immunofluorescence was performed on Fibronectin (Merck, cat. FC010) coated glass coverslips.
944 Cells were fixed for 10 min with 4% Formaldehyde at RT, followed by permeabilization in PBS +
945 0.5% Triton X-100 for 20 min at RT and blocking with PBS+0.5% Triton X-100 + 3% FBS for 1
946 hour at RT. Cells were incubated with primary antibodies in blocking solution overnight at 4°C.
947 After washing with PBS, cells were incubated for 30 min at RT with Alexa Fluor-conjugated
948 secondary antibodies (Life Technologies) used at 1:500 dilution. After washing with PBS, cells
949 were mounted with Fluoroshield with DAPI (Sigma Aldrich, F6057). Images were acquired with
950 Leica SP5 confocal microscope equipped with a charge-couples device camera, using the LAS
951 AF software. Antibodies are listed in Supplementary Table 6. For image analysis, Cell Profiler
952 was used to quantify mean fluorescence intensity for each nucleus.

953

954 **Western blot**

955 Total cell extracts were obtained by lysing cell pellets in Sonication buffer (10mM HEPES pH7.8,
956 150mM NaCl, 5mM EDTA, 5% glycerol, 0.5% NP40) with the addition of protease inhibitors
957 (Sigma Aldrich, P8340) and 1mM DTT, and sonicated briefly with Bioruptor. PVDF membranes
958 were blocked with 5% milk in TBST 0.5% for 1h at RT. Primary antibodies were incubated
959 overnight at 4°C. HRP-conjugated secondary antibodies were incubated for 1h at RT. Images
960 were digitally acquired using a ImageQuant LAS 4000 (GE Healthcare) and its proprietary
961 software. Antibodies are listed in Supplementary Table 6.

962

963 **Chromatin immunoprecipitation for ChIP-PCR**

964 For ChIP-PCR, cell suspension was crosslinked with 1/10 volume of fresh Formaldehyde solution
965 (11% methanol free Formaldehyde, 100mM NaCl, 1mM EDTA, 0.5mM EGTA, 50mM HEPES) in
966 culture medium and incubated for 8 min at RT on an orbital shaker. Formaldehyde was quenched
967 by adding 1/20 volume of 2.5M Glycine. After 2 min incubation at RT, cells were centrifuged at
968 500g for 3 min and cell pellet was washed twice with ice cold PBS+PIC before storage at -80°C.
969 To obtain nuclear lysates, pellets from fixed cells were resuspended (1ml/10⁷ cells) in ice cold
970 LB1 buffer (10mM NaCl, 1mM EDTA, 50mM HEPES pH 7.5, 10% glycerol, 0.5% NP40, 0.25%
971 Triton X-100) +PIC, rotated for 20min at 4°C and spun for 5min at 1500g in a table top centrifuge.
972 Cell pellet was resuspended (1mL/10⁷ cells) in ice cold LB2 buffer (10mM Tris Hcl pH8, 200mL
973 NaCl, 1mM EDTA, 0.5mM EGTA) +PIC, rotated for 10 min, spun at 1500g for 5 min and
974 resuspended in LB3 buffer (10mM Tris-Hcl pH8, 1mM EDTA, 100mM NaCl, 0.5mM EGTA, 0.1%
975 Na-deoxycholate, 0.5% N-lauroylsarcosine) +PIC. Nuclear lysates were sonicated with Branson
976 Sonifier 450A for 8 cycles (1minON/ 2min OFF) to obtain DNA fragments with an average size of
977 400bp.
978 60ug of DNA were diluted in 600uL LB3+PIC and 10 uL of Dynabeads protein G (Life
979 Technologies) were added. Samples were rotated for 3h at 4°C. Supernatants were then
980 incubated overnight at 4°C with 2ug of appropriate primary antibody or IgG in a rotating wheel,
981 followed by incubation with 10uL of Protein G Dynabeads for 2h at 4°C. Beads were collected
982 with a magnetic stand and were then washed 3 times (5min each on a rotating wheel) with 1mL
983 of low salt wash buffer (0.1% SDS, 2mM EDTA, 1% Triton X-100, 20mM Tris pH8, 150mM NaCl)
984 at 4°C, followed by one wash in high salt wash buffer (0.1% SDS, 2mM EDTA, 1% Triton X-100,
985 20mM Tris pH8, 500mM NaCl), one wash with LiCl buffer (250mM LiCl, 1% NP40, 1mM EDTA,
986 10mM Tris pH8) and one wash with 1mL TE buffer +50mM NaCl. Chromatin-antibody complexes
987 were eluted by incubating in 210uL of Elution buffer (50mM Tris-HCl pH8, 10mM EDTA, 1% SDS)
988 on a shaker block at 65°C for 20min followed by centrifugation at 16000g for 1min. Reverse

989 crosslinking was performed by incubating at 65°C overnight. DNA was purified with Qiagen
990 QIAquick PCR Purification kit.

991 The following antibodies and cell number were used for each ChIP replicate: ESRRB ChIP: 3x10⁷
992 cells, 2ug mouse ESRRB antibody (Perseus cat.PP-H6705-00); H3K27ac ChIP: 3x10⁶ cells,
993 2.5ug rabbit H3K27ac antibody (Abcam cat.ab4729).

994

995 **Chromatin immunoprecipitation library preparation and sequencing**

996 10⁷ cells were fixed with 1% formaldehyde for 15 minutes at room temperature. Samples for ChIP-
997 seq were prepped as previously described⁸⁶.

998 Libraries were prepared from 10 ng of DNA using the NEBNext® Ultra™ II DNA Library Prep Kit
999 for Illumina (New England Biolabs). Quality of libraries was assessed by using Bioanalyzer DNA
1000 Analysis (Agilent Technologies), and quantified by using Qubit 4 Fluorometer (Thermo Fisher
1001 Scientific).

1002 Libraries were sequenced on a NovaSeq 6000 sequencing system using a paired-end (PE) 100
1003 cycles flow cell (Illumina Inc.).

1004

1005 **ChIP-sequencing bioinformatic analyses**

1006 Paired sequencing reads were aligned on mouse mm10 reference genome using BWA (v0.7.17)⁸⁷
1007 and filtered with samtools v(1.9)⁸⁸ to remove unmapped read pairs, not primary alignment, reads
1008 failing platform quality, with mapping quality score below 30 and duplicate reads were then
1009 removed using picard MarkDuplicates (“Picard Toolkit.” 2019. Broad Institute, GitHub Repository.
1010 <https://broadinstitute.github.io/picard/>) (v.2.18.27).

1011 Each sample was equally split in two pseudoreplicates, peaks were called with MACS2 (v2.2.5)⁸⁹
1012 with p < 0.1 on both samples and pseudoreplicates and filtered after Irreproducible Discovery
1013 Rate analysis with a threshold of 0.05. Coverage signal profile was generated with deeptools⁹⁰
1014 using CPM normalisation.

1015

1016 **ATAC-seq and bioinformatic analyses**

1017 ATAC-seq libraries were prepared starting from cryopreserved cells aliquots containing
1018 approximately 0.4 million cells. Each aliquot was thawed by brief warming at 37°C in a water bath,
1019 dropwise transferred into 10 mL warm 1X PBS (Euroclone, #ECB4004) and then centrifuged at
1020 200 rcf for 5 minutes. Cell pellet was resuspended in 1 mL of warm 1X PBS and 10 uL of
1021 suspension were used for cell counting. ATAC-seq libraries (two for each condition) were
1022 generated starting from 100,000 live cells for each sample⁹¹. Ten PCR cycles were performed
1023 for each library using a SimplyAmp (Applied Biosystems, #A24811) thermal cycler. Finally, the
1024 libraries were run on a 2% agarose gel using the E-gel electrophoresis system (ThermoFisher,
1025 #G6400EU) for size selection. Fragments ranging from 200 bp to 700 bp were then purified using
1026 the Zymoclean Gel DNA Recovery Kit (Zymo Research, #D4007). Sequencing was performed
1027 using 2x50 bp reads on an Illumina Novaseq-6000. Libraries pool was load on a S1 flowcell at
1028 the final concentration of 250 pM using 1% PhiX.

1029 Paired sequencing reads were aligned on mouse mm10 reference genome using BWA (v0.7.17)⁸⁷
1030 and filtered with samtools (v1.9)⁸⁸ to remove unmapped read pairs, not primary alignment, reads
1031 failing platform quality, with mapping quality score below 30 and duplicate reads were then
1032 removed using picard MarkDuplicates (Picard Toolkit." 2019. Broad Institute, GitHub Repository.
1033 <https://broadinstitute.github.io/picard/>) (v2.18.27). Peaks were called using the ENCODE ATAC-
1034 seq pipeline⁹² (<https://github.com/ENCODE-DCC/atac-seq-pipeline>) (v1.10.0) using an IDR
1035 threshold of 0.05.

1036 TF motifs enrichment analysis on promoter-annotated peaks (+-2kb from the TSS) was carried
1037 out using Homer's findMotifsGenome⁹³ (-size given) for de novo motif discovery. Only
1038 transcription factors with a percentage of targets > 8 were considered.

1039

1040 **CUT&RUN-seq analysis**

1041 Cleavage Under Targets and Release Using Nuclease sequencing (CUT&RUN-seq)⁹⁴ data,
1042 generated in Gretarsson and colleagues⁹⁵, were analysed as follows: raw Fastq-sequences were
1043 trimmed to remove adaptors with TrimGalore (v0.4.3.1, -phred33 --quality 20 --stringency 1 -e 0.1
1044 --length 20), quality checked and aligned to the mouse mm10 genome using Bowtie2 (v2.3.4.2, -
1045 l 50 -X 800 --fr -N 0 -L 22 -i 'S,1,1.15' --n-ceil 'L,0,0.15' --dpad 15 --gbar 4 --end-to-end --score-
1046 min 'L,-0.6,-0.6'). Analysis of the mapped sequences was performed using Seqmonk (v1.46.0)
1047 and R statistical software (v4.0.4)

1048

1049 **Generation of *Esrrb*-knockout in SGET ESC for PGCLC specification**

1050 For analysis of PGCLC induction, *Esrrb* KO cells were generated in the *Stella*-GFP:*Esg1*-
1051 tdTomato (SGET) compound-reporter mESC line⁵⁷. Briefly, two spCas9 plasmids (pX459
1052 Addgene #62988) carrying gRNAs that induce deletions of exons 2 and 3 (gRNAs sequences are
1053 listed in Supplementary Table 5) were transiently transfected with lipofectamine 3000, following
1054 the manufacturers guidelines. Transfected cells were selected with puromycin (1.2 µg/ml) for 60
1055 hours and subsequently seeded at low density (1000 cells per 9.6cm²) for single colony picking.
1056 After clonal expansion, homozygous knock-out clones were identified by PCR genotyping and
1057 confirmed by western blot. Three independent clonal WT and *Esrrb* KO cell lines were selected
1058 for further analysis.

1059

1060 **Cell culture and PGCLC induction**

1061 *Esrrb* KO SGET ESCs were routinely maintained and regularly passaged on gelatin in 2i/L culture
1062 media (NDIFF 227 supplemented with PD0325901 (1 µM), CHIR99021 (3µM), LIF (1000 U/ml),
1063 FBS (1%) and penicillin/streptomycin (1%)); filtered through 0.22 µM filter) in a humidified CO₂
1064 incubator at 37°C. Epiblast-like cells (EpiLC) were induced by seeding 3x10⁴ naive ESC per cm²
1065 on fibronectin-coated plates and maintained in EpiLC media (NDIFF 227 supplemented with
1066 knockout serum replacement (KSR) (1%), ActivinA (20 ng/ml), bFGF (12.5 ng/ml) and

1067 penicillin/streptomycin (1%)) for 46 hours. For subsequent induction of PGCLC, 1.5×10^6 EpiLC
1068 were seeded per well of an ultra-low attachment microwell 6-well plate (Iwaki 4810-900) using
1069 PGCLC culture media (GMEM supplemented with KSR (15%), NEAA (0.1 mM), Sodium Pyruvate
1070 (1 mM), Penicillin/Streptomycin(1%), B-mercaptoethanol (0.1mM), L-glutamine (1mM), BMP4
1071 (500 ng/ml), LIF (1000 U/ml), SCF (100 ng/ml), BMP8a (500 ng/ml), EGF (50 ng/ml). A half-media
1072 change was performed every day. See Supplementary Fig. 3 for the gating strategy used.

1073

1074 **Flow-cytometry of *Esrrb* KO SGET lines**

1075 After dissociation in single cell suspension using TrypLE, *Esrrb* KO or WT SGET PGCLC at 3- or
1076 5- days induction were resuspended in PBS/1%FBS and filtered. PGCLC were isolated using
1077 fluorescent activated cell sorting with FACS Aria III (Becton Dickinson) and FACS diva software
1078 (v9.0), according to *Stella*-GFP (SG) and *Esg*-tdTomato (ET) expression that is indicative of
1079 authentic PGCLC (SG⁺ET^{low}). Data analysis was performed with FlowJo software (v10.7.1).

1080

1081 **RNA sequencing of *Esrrb* KO EpiLC and PGCLC**

1082 Total RNA was collected from *Esrrb* KO or WT bulk ESC, EpiLC and from sorted SG⁺ET^{low} PGCLC
1083 of three independent biological replicates lines using the PicoPure RNA isolation kit (Applied
1084 Biosystems KIT0204), following the manufacturer instructions. After quantification of total RNA
1085 with Qubit III and quality check with high sensitivity RNA Screen Tape (Agilent 5067-5579) to
1086 ensure RIN > 8.5, 100ng of RNA was used for library preparation for NGS sequencing with NEB
1087 next Ultra II Directional RNA protocol for Poly(A) mRNA magnetic Isolation Module (NEB #E7490)
1088 following manufacturer guidelines. Multiplexed amplified libraries were sequenced on an Illumina
1089 NextSeq (SE50).

1090

1091 **Bioinformatics analysis of RNA sequencing data for EpiLC and PGCLC**

1092 After removal of the adaptors with TrimGalore (0.4.3.1) raw reads were mapped to the mm10
1093 (GRCm38) reference genome with RNASTAR (2.6.0b-2) using default settings. Reads associated
1094 with a MAPQ score <20 were discarded. The data was quantified using the RNA-seq
1095 quantification pipeline for directional libraries in seqmonk software (v1.46.0) to generate log₂
1096 reads per million (RPM) or gene-length-adjusted (RPKM) gene expression values. We determined
1097 differentially expressed genes (DEG) using the DESeq2 package (version, 1.24.0) and applying
1098 a multiple-testing adjusted *p-value* (FDR) <0.05 significance threshold.

1099

1100 **Computational modelling**

1101 The computational modelling was performed using the reasoning engine for interaction networks
1102 (RE:IN)^{17,63,96}. This approach supports the modelling of gene networks via Abstract Boolean
1103 Networks (ABN), allowing to specify partially known networks by specifying certain interactions
1104 as definite while other interactions are designated as possible. In this logical modelling setting, an
1105 ABN contains a set of components which can be active or inactive (represented by a Boolean
1106 value). The networks are constrained by experimental observations obtained from experimental
1107 measurements, and formal verification methods are utilised to handle the large state space of
1108 candidate solutions and identify consistent models when they exist or prove inconsistency which
1109 requires a revision of the model. The methodology has proven to be applicable to study stem cell
1110 systems and the implementation has been extended to support integration of new analysis
1111 procedures and support the use of computational notebooks. The source code is publicly
1112 available on GitHub (<https://github.com/fsprojects/ReasoningEngine>), together with the files used
1113 to build the ABN (<https://github.com/kuglerh/Esrrb>).

1114 The initial ABN (Extended Data Fig. 8g) was constructed from the experimentally validated ABN
1115 (0.717 cABN) described by Dunn and collaborators³⁹. We added the formative genes Etv5, Tcf15,
1116 Dnmt3a/b, Otx2, Utf1, Lef1, Pou3f1^{19,28,29}. We kept the 0.717 cABN definite interactions,
1117 connecting the signals LIF, CH and FGF to the network, and added a positive interaction between

1118 MEK/ERK and ETV5. All these interactions are based on previous experimental studies that
1119 identified the direct targets of these signals^{24,26,28,44,97,98}. We also kept the additional 0.717 cABN
1120 interactions as possible. We then derived a set of possible interactions from time course gene
1121 expression data (Fig. 1c-d), by calculating Pearson's correlation coefficients (shown in Fig. 7e).
1122 A positive interaction between two components was defined as possible when the coefficient
1123 between the two components was above a threshold value. A negative possible interaction was
1124 set when the Pearson's coefficient was below the negative of the threshold value. A threshold
1125 value of 0.55 was determined by constructing a set of experimental constraints (Extended Data
1126 Fig. 8h), and looking for the maximum Pearson coefficient threshold that could satisfy those
1127 constraints, as described before in^{17,63}. Additional possible interactions were obtained from CHIP-
1128 seq data (Fig. 3f-g).

1129 Experimental constraints were obtained by discretising expression measurements. We started
1130 from the 2iL time course data, calculated the maximum expression value of each component and
1131 for each time point we assigned to that component a Boolean value of 1 if its expression was
1132 above 0.5 of the maximum value. The naive, formative and committed states correspond to 2iL,
1133 48h and 96h time points, and we also included protein expression levels for Esrrb (Fig. 2h). Esrrb
1134 KO constraints were derived from time course RNAseq data of Fig. 5c-e, following the procedure
1135 described above, while Esrrb conditional KO data are based on Extended Data Fig. 5b. After
1136 verifying that all experimental constraints were satisfiable, we identified required and disallowed
1137 interactions (shown in Extended Data Fig 8g). We then generated a set of model solutions and
1138 picked a representative one, which was used to calculate trajectories and generate the network
1139 diagrams shown in Fig. 7f-g.

1140

1141 **Statistics and reproducibility**

1142 No statistical method was used to predetermine sample size, but our sample sizes are similar to
1143 those reported in previous publications^{28,48,60}. No data were excluded from the analyses. Data

1144 distribution was assumed to be normal but this was not formally tested. For experiments with cells
1145 lines, we randomly allocated a fraction of each cell population to different biological replicates.
1146 For the analysis of immunostaining and flow cytometry data, we analysed random fields or
1147 random fraction of cells. Other kind of experiments were not randomized. Data collection and
1148 analysis were not performed blind to the conditions of the experiments, but data analyses have
1149 been performed with identical parameters and software. Data representation and statistical
1150 analyses were performed using R software, unless stated otherwise. The statistical tests used
1151 are indicated in figure legends. The number of biological replicates and independent experiments,
1152 both >2, is indicated in figures legends. Key experimental results have been obtained by 2
1153 independent operators.

1154

1155 **Data availability**

1156 Sequencing data that support the findings of this study have been deposited in the Gene Expression
1157 Omnibus (GEO) under accession code GSE184137. Previously published RNAseq and CUT&RUN data
1158 that were re-analysed here are available under accession codes GSE23943 and GSE146863. Primers,
1159 oligonucleotides sequences and antibodies are present in Supplementary Tables 4, 5 and 6.
1160 Source data are provided with this study. All other data supporting the findings of this study are available
1161 from the corresponding author on reasonable request.

1162

1163 **Code availability**

1164 Data files and models used to build the ABN are available at <https://github.com/kuglerh/Esrrb>.
1165 The code used to build the ABN has been described in^{17,39,63} and made publicly available on
1166 GitHub at: <https://github.com/fsprojects/ReasoningEngine>.

1167

1168

1169 Methods-only references

- 1170 75. Handyside, A. H., O'Neill, G. T., Jones, M. & Hooper, M. L. Use of BRL-conditioned medium
1171 in combination with feeder layers to isolate a diploid embryonal stem cell line. *Roux's Arch.*
1172 *Dev. Biol. Off. Organ EDBO* **198**, 48–56 (1989).
- 1173 76. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinforma. Oxf. Engl.* **29**, 15–21
1174 (2013).
- 1175 77. Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with high-throughput
1176 sequencing data. *Bioinforma. Oxf. Engl.* **31**, 166–169 (2015).
- 1177 78. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for
1178 differential expression analysis of digital gene expression data. *Bioinforma. Oxf. Engl.* **26**,
1179 139–140 (2010).
- 1180 79. Kalaitzis, A. A. & Lawrence, N. D. A simple approach to ranking differentially expressed
1181 gene expression time courses through Gaussian process regression. *BMC Bioinformatics*
1182 **12**, 180 (2011).
- 1183 80. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model
1184 analysis tools for RNA-seq read counts. *Genome Biol.* **15**, R29 (2014).
- 1185 81. Chen, E. Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment analysis
1186 tool. *BMC Bioinformatics* **14**, 128 (2013).
- 1187 82. Fast gene set enrichment analysis | bioRxiv.
1188 <https://www.biorxiv.org/content/10.1101/060012v3>.
- 1189 83. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids*
1190 *Res.* **28**, 27–30 (2000).

- 1191 84. Kuleshov, M. V. *et al.* Enrichr: a comprehensive gene set enrichment analysis web server
1192 2016 update. *Nucleic Acids Res.* **44**, W90-97 (2016).
- 1193 85. Xie, Z. *et al.* Gene Set Knowledge Discovery with Enrichr. *Curr. Protoc.* **1**, e90 (2021).
- 1194 86. Cacchiarelli, D. *et al.* Integrative Analyses of Human Reprogramming Reveal Dynamic
1195 Nature of Induced Pluripotency. *Cell* **162**, 412–424 (2015).
- 1196 87. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform.
1197 *Bioinforma. Oxf. Engl.* **25**, 1754–1760 (2009).
- 1198 88. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *GigaScience* **10**, giab008
1199 (2021).
- 1200 89. Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* **9**, R137 (2008).
- 1201 90. Ramírez, F. *et al.* deepTools2: a next generation web server for deep-sequencing data
1202 analysis. *Nucleic Acids Res.* **44**, W160-165 (2016).
- 1203 91. Corces, M. R. *et al.* An improved ATAC-seq protocol reduces background and enables
1204 interrogation of frozen tissues. *Nat. Methods* **14**, 959–962 (2017).
- 1205 92. Dunham, I. *et al.* An integrated encyclopedia of DNA elements in the human genome.
1206 *Nature* **489**, 57–74 (2012).
- 1207 93. Heinz, S. *et al.* Simple Combinations of Lineage-Determining Transcription Factors Prime
1208 cis-Regulatory Elements Required for Macrophage and B Cell Identities. *Mol. Cell* **38**, 576–
1209 589 (2010).
- 1210 94. Skene, P. J. & Henikoff, S. An efficient targeted nuclease strategy for high-resolution
1211 mapping of DNA binding sites. *eLife* **6**, e21856 (2017).
- 1212 95. Gretarsson, K. H. & Hackett, J. A. Dppa2 and Dppa4 counteract de novo methylation to
1213 establish a permissive epigenome for development. *Nat. Struct. Mol. Biol.* **27**, 706–716
1214 (2020).
- 1215 96. Yordanov, B., Dunn, S.-J., Gravill, C., Kugler, H. & Wintersteiger, C. M. An SMT-Based
1216 Framework for Reasoning About Discrete Biological Models. in *Bioinformatics Research and*

- 1217 *Applications* (eds. Bansal, M. S., Cai, Z. & Mangul, S.) 114–125 (Springer Nature
1218 Switzerland, 2022). doi:10.1007/978-3-031-23198-8_11.
- 1219 97. H, N., K, O., D, S. & K, A. A parallel circuit of LIF signalling pathways maintains pluripotency
1220 of mouse ES cells. *Nature* **460**, (2009).
- 1221 98. Silva, J. *et al.* Nanog is the gateway to the pluripotent ground state. *Cell* **138**, 722–737
1222 (2009).




Fig.1




Fig.2







Fig.3

a**c****b****Fig.4**









Fig.5









a**b**


Extended Data Fig.1




Extended Data Fig.2




Extended Data Fig.3




Extended Data Fig.4




b




c




d







Extended Data Fig.6




Extended Data Fig.7



Extended Data Fig.8



Extended Data Fig.9



Extended Data Fig.10